





2017-2018

24th Annual Report



Expanding the Horizons with Quality
Expanding the Horizons with Quality

Corporate Information**BOARD OF DIRECTORS**

Mr. Peeyush Kumar Aggarwal	Director	(DIN : 00090423)
Mr. Sachin Garg	Managing Director	(DIN : 03320351)
Mr. Manoj Kumar Jain	Independent Director	(DIN : 02573858)
Ms. Madhu Sharma	Independent Director	(DIN : 06947852)

COMPANY SECRETARY

Ms. Pooja Chuni
Company Secretary

CHIEF FINANCIAL OFFICER

Mr. Manoj Kumar Bhatia
Chief Financial Officer (CFO)

AUDITORS

M/s RMA & Associates, LLP
Chartered Accountants
(Firm Registration No. 000978N/N500062)

BANKERS

Indian Overseas Bank, New Delhi
HDFC Bank, New Delhi

REGISTRAR & SHARE TRANSFER AGENTS

MAS Services Limited
SEBI Registration No. INR000000049
T-34, IInd Floor, Okhla Industrial Area, Phase II,
Delhi - 110020
New Delhi -110 062
Tel: 91-11-26387281
Fax: 91-11-26387384
E-mail: info@masserv.com
Website: www.masserv.com

CORPORATE OFFICE:

703, Arunachal Building, 19
Barakhamba Road, Connaught Place,
New Delhi-110 001(INDIA)
Tel No.: 91-11-43571040-45
FAX : 91-11-42424884
E-Mail: mail@advikindia.com
Website: www.advikindia.com

REGISTERED OFFICE & PLANT:

138, Roz-Ka-Meo, Industrial Area,
Sohna, Distt. -Mewat (Haryana) INDIA
Tel. No.: 0124-2362471,+91-9813179885

CIN: L74899HR1994PLC038300

Notice

Notice is hereby given that the 24TH (Twenty Fourth) Annual General Meeting of the Members of **ADVIK LABORATORIES LIMITED** will be held on Friday, 28th September, 2018 at 10.00 A.M. at its Registered Office at 138, Roz- Ka - Meo, Industrial Area Sohna, Distt. Mewat-122 103 (Haryana) INDIA to transact the following business:

Ordinary Business:

1. To receive, consider and adopt the Audited Financial Statements of the company including the Balance Sheet of the Company as at 31st March, 2018 and the Statement of Profit and Loss of the Company for the financial year ended 31st March, 2018 together with the Cash Flow Statement & other Annexure thereof and the Reports of the Board of Directors and Auditors thereon.
2. To appoint a Director in place of Mr. Sachin Garg (DIN 03320351), the Managing Director of the Company, who is liable to retire by rotation and being eligible, offers himself for re-appointment pursuant to the provisions of Section 152 of the Companies Act, 2013.
3. To re-appoint M/s RMA & Associates LLP, the Statutory Auditors' of the Company (Firm Registration No. . 000978N/N500062), for a further term of 5 years and in this connection to consider, and, if thought fit, to pass, with or without modification, the following resolution, as an Ordinary Resolution:

“RESOLVED THAT pursuant to Section 139, 142 and other applicable provisions of Companies Act, 2013, if any, read with the Companies (Audit & Auditors) Rules, 2014 (including any statutory enactment or modification(s) thereof, for the time being in force) and SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 and any other Act, as may be applicable to the Company for the time being in force, and pursuant to the recommendation of the Audit Committee, M/s RMA & Associates LLP, Chartered Accountants, New Delhi (Firm Registration No. 000978N/N500062), the Company's retiring auditors, being eligible and offering themselves for reappointment, be and are hereby reappointed as the Statutory Auditors of the Company for a further term of Five (5) years, to hold office from the conclusion of 24th Annual General Meeting until the conclusion of 29th Annual General Meeting of the Company on such remuneration and out of pocket expenses, as may be decided by the Board of Directors of the Company and Statutory Auditors'.”

Special Business:

4. To consider and if thought fit, to pass, with or without modification, the following resolution as an Ordinary Resolution.

“RESOLVED THAT pursuant to provisions of Section 188 and other applicable provisions, if any, of the Companies Act, 2013 read with applicable Rules under Companies (Meetings of Board and its Powers) Rules, 2014 and in terms of applicable provisions of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 (including any amendment, modification or re-enactment thereof), and subject to such other approvals from such Authorities as may be required in this regard, the consent of the members of the Company be and is hereby accorded to the Board of Directors of the Company to sale, purchase or supply of any goods or materials, selling or otherwise disposing of, or buying, leasing of property of any kind, availing or rendering of any services, appointment of agent for purchase or sale of goods, materials, services or property or otherwise disposing of any goods, materials or property or availing or rendering any services from related parties or appointment of such related party to any office or place of profit in the company or its associate companies, if any or reimbursement of any transaction or any other transaction of whatever nature with related parties:

Sr. No	Name of the Related Party	Relationship	Maximum Value of Transactions per annum with effect from April 01, 2018 (Rs. in lacs)
1	Mr. Peeyush Kumar Aggarwal	Director & Promoter of the Company	50.00*
2	Omkam Global Capital Pvt. Ltd.	Mr. Peeyush Kumar Aggarwal, Director & Promoter of the Company is also a Director & Promoter of Omkam Global Capital Pvt. Ltd.	800.00*
3	Omkam Developers Limited	Mr. Peeyush Kumar Aggarwal, Director & Promoter of the Company is also a Director & Promoter of Omkam Developers Limited.	600.00*

* Expected maximum annual value of transactions per related party over the year

“RESOLVED FURTHER THAT the board of directors of the Company be and is hereby authorized to take such steps as may be necessary for obtaining approvals, statutory, contractual or otherwise, in relation to the above and to settle all matters arising out of and incidental thereto, and to sign and execute all deeds, applications, documents and writings that may be required, on behalf of the Company and generally to do all acts, deeds, matters and things that may be necessary, proper, expedient or incidental thereto for the purpose of giving effects to this Resolution.

For and on Behalf of the Board of Directors of
Advik Laboratories Ltd.

Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423

Date: 01st September, 2018
Place: New Delhi

Notes:

1. Explanatory Statement as required under Section 102(1) of the Companies Act, 2013 (the Act), relating to the Special Business to be transacted at the meeting is annexed.
2. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF AND A PROXY NEED NOT BE A MEMBER OF THE COMPANY. A PROXY FORM IS ENCLOSED. THE INSTRUMENT APPOINTING A PROXY SHOULD, HOWEVER, BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING.

A person can act as a proxy on behalf of members not exceeding fifty and holding in aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A member holding more than ten per cent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act proxy for any other person or member.

3. Corporate Members intending to send their authorized representative to attend the Meeting are requested to send at the Registered Office of the Company, a duly certified copy of the Board Resolution, authorising their representative to attend and vote on their behalf at this General Meeting.
4. Queries proposed to be raised at the Annual General Meeting may be sent to the Company at its registered office at least seven days prior to the date of Annual General Meeting to enable the management to keep the information ready at the meeting.
5. The Register of Members and Share Transfer Books of the Company will remain closed from Saturday, 22nd September, 2018 to Friday, 28th September, 2018 (both days inclusive) for the purpose of the AGM.
6. **Members / Proxies should fill-in the attendance slip for attending the Meeting and bring their attendance slip along with their copy of the Annual Report to the Meeting.**
7. In case of joint holders attending the meeting, only such joint holder who is higher in the order of name will be entitled to vote.
8. Members who are holding Company's shares in dematerialized form are required to bring details of their Depository Account Number for identification.
9. The members are requested to intimate changes, if any, in their registered address to the Registrar & Share Transfer Agents for shares held in physical form & to their respective Depository participants for shares held in electronic form.
10. All documents referred to in the accompanying Notice are opened for inspection at the Registered Office of the Company on all working days, except Sunday between 2 P.M. to 4 P.M. upto the date of the Annual General Meeting.

11. Members are requested :
- To quote their folio Nos. in all correspondence.
 - To note that no gifts will be distributed at the meeting.
 - In case of joint holders attending the meeting, only such joint holder who is higher in the order of names will be entitled to vote.
12. **Members who have not registered their e-mail addresses so far are requested to register their e-mail addresses for receiving all communications including Annual Report, Notices, Circulars, etc from the Company electronically.**
13. In terms of Section 72 of the Companies Act, 2013, a Member of the Company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Member(s) desirous of availing this facility may submit nomination in the prescribed Form SH – 13 to the Company/RTA in case shares are held in Physical form, and to their respective depository participant, if held in electronic form.
14. **Members/Promoters holding shares in demat form are requested to submit their Permanent Account Number (PAN), to their respective Depository Participant and those holding shares in physical form are requested to submit their PAN details as well as to get their shares dematerialized to the company on and before 5th December, 2018. Pursuant to SEBI notification number SEBI/LAD-NRO/GN/2018/24 dated June 08, 2018. Please note that as per the aforesaid SEBI's notification, the requests for effecting transfer of securities shall not be processed after 05th December, 2018 unless the securities are held in dematerialised form with a Depository. In view of the above all the shareholders holding shares in physical form are requested to open a de-mat A/c with a Depository participants and get their shares dematerialised. Necessary communication in this regard has already been sent separately to the shareholders by the company.**
15. **Members/Promoters holding shares, of the Company in demat form shall provide the details of their Bank Account and E-mail Id to the RTA i.e MAS Services Limited having registered office is T-34, IInd Floor, Okhla Industrial Area, Phase-II, New Delhi 110020 and those holding shares in physical form will provide their Bank A/c details and E-mail Id to the Company. Necessary communication in this regard has already been sent separately to the shareholders by the company.**
16. Pursuant to Section 108 of the Companies Act, 2013, read with the Companies (Management and Administration) Rules, 2014, the Company is pleased to provide the e-voting facility to the members to exercise their right to vote by electronic means. The Company has fixed 21st September, 2018 as a cut – off date to record the entitlement of the shareholders to cast their vote electronically at the 24th Annual General Meeting (AGM) by electronic means under the Companies Act, 2013 and rules thereunder. Consequently, the same cut-off date, i.e., 21st September, 2018 would record entitlement of the shareholders, who do not cast their vote electronically, to cast their vote at the 24th AGM on 28th September, 2018.

The e-voting period will commence at 9.00 A.M. on 25th September, 2018 and will end at 05.00 P.M. on 27th September, 2018. The Company has appointed Mr. Kundan Agrawal (Membership No. FCS- 7631& CP No. 8325), Company Secretary in Practice to act as Scrutinizer, for conducting the scrutiny of the votes cast. The Members desiring to vote through electronic mode may refer to the detailed procedure on e-voting given as Annexure to the Notice.

The Company has engaged the services of **National Securities Depository Limited (NSDL)** as the Authorised Agency to provide remote e-voting facility.

For and on Behalf of the Board of Directors of
Advik Laboratories Ltd.

Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423

Date: 01st September, 2018
Place: New Delhi

VOTING THROUGH ELECTRONIC MEANS

VOTING THROUGH ELECTRONIC MEANS

The procedure and instructions for e-voting as given in the Notice of the 24th Annual General Meeting are again reproduced hereunder for easy reference:

- I. **In case of Members receiving e-mail from NSDL (For those members whose e-mail addresses are registered with Company/Depositories):**
 - a. Open e-mail and open PDF file viz."Advik-remote e-Voting.pdf" with your client ID or Folio No. as password containing your user ID and password for remote e-voting. Please note that the password is an initial password.
 - b. Launch internet browser by typing the following URL: <https://www.evoting.nsdl.com/>. Or <https://www.evotingindia.com/>
 - c. Click on Shareholder-Login.
 - d. Put user ID and password as initial password noted in step (i) above. Click Login.
 - e. Password change menu appears. Change the password with new password of your choice with minimum 8 digits/characters or combination thereof. Note new password. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
 - f. Home page of remote e-voting opens. Click on remote e-voting: Active Voting Cycles.
 - g. Select "EVEN" of "Advik Laboratories Limited". The "EVEN" of Advik Laboratories Limited is 109807.
 - h. Now you are ready for remote e-voting as Cast Vote page opens.
 - i. Cast your vote by selecting appropriate option and click on "Submit" and also "Confirm" when prompted.
 - j. Upon confirmation, the message "Vote cast successfully" will be displayed.
 - k. Once you have voted on the resolution, you will not be allowed to modify your vote.
 - l. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer through e-mail to cskundanagerawal@gmail.com with a copy marked to mail@advikindia.com and evoting@nsdl.co.in.
- II. **In case of Members receiving Physical copy of Notice of 24th Annual General Meeting (for members whose e-mail IDs are not registered with the Company/Depository Participants(s) or requesting physical copy)**
 - a. Initial password is provided in the box overleaf.
 - b. Please follow all steps from Sl. No. (b) to Sl. No. (l) above, to cast vote.
 - A. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Members and remote e-voting user manual for Members available at the downloads section of www.evoting.nsdl.com or call on toll free no.: 1800-222-990.
 - B. If you are already registered with NSDL for remote e-voting then you can use your existing user ID and password/PIN for casting your vote.
 - C. You can also update your mobile number and e-mail id in the user profile details of the folio which may be used for sending future communication(s).
 - D. The voting rights of members shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date of 21st September 2018.
 - E. Any person, who acquires shares and becomes member of the Company after dispatch of the notice and holding shares as of the cut-off date i.e., 21st September 2018, may also obtain the login ID and password by sending a request at evoting@nsdl.co.in or RTA, MAS Services Limited. However, if you are already registered with NSDL for remote e-voting then you can use your existing user ID and password for casting your vote. If you forgot your password, you can reset your password by using "Forgot User Details/Password" option available on www.evoting.nsdl.com or contact NSDL at the following toll free no.: 1800-222-990.
 - F. A member may participate in the AGM even after exercising his right to vote through remote e-voting but shall not be allowed to vote again at the AGM.
 - G. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting as well as voting at the AGM through ballot paper.

- H. Mr. Kundan Agrawal Practicing Company Secretary (Membership No. FCS –7631 & CP No. 8325), has been appointed for as the Scrutinizer for providing facility to the members of the Company to scrutinize the voting and remote e-voting process in a fair and transparent manner.
- I. The e-voting period will commence at 09.00 A.M. on 25th September, 2018 and will end at 05.00 P.M. on 27th September, 2018.
- J. The Chairman shall, at the AGM, at the end of discussion on the resolutions on which voting is to be held, allow voting with the assistance of scrutinizer, by use of “Ballot Paper” for all those members who are present at the AGM but have not cast their votes by availing the remote e-voting facility.
- K. The Scrutinizer shall after the conclusion of voting at the AGM, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than three days of the conclusion of the AGM, a consolidated scrutinizer’s report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
- L. The Results declared alongwith the report of the Scrutinizer shall be placed on the website of the Company www.advikindia.com and on the website of NSDL immediately after the declaration of result by the Chairman or a person authorized by him in writing and communicated to the BSE Limited and ASE Limited.
- M. Once the vote on a resolution is cast by a member, the member shall not be allowed to change it subsequently or cast the vote again.

**For and on Behalf of the Board of Directors of
Advik Laboratories Ltd.**

**Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423**

**Date: 01st September, 2018
Place: New Delhi**

ANNEXURE TO THE NOTICE

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013

Item No. 4:

The Companies Act, 2013 aims to ensure transparency in the transactions and dealings with the related parties of the Company. The provisions of Section 188(1) of the Companies Act, 2013 that govern the Related Party Transactions, require that for entering into any contract or arrangement as mentioned herein below with the related party, the Company must obtain prior approval of the Board of Directors and in case of the Company having a paid up capital of Rs. Ten Crores or more, prior approval of shareholders must be obtained for entering into following Related Party Transactions:

1. Sale, purchase or supply of any goods or materials,
2. Selling or otherwise disposing of, or buying, leasing of property of any kind,
3. Availing or rendering of any services,
4. Appointment of any agent for purchase or sale of goods, materials, services or property or otherwise disposing of any goods, materials or property or availing or rendering any services from related parties,
5. Appointment of such related party to any office or place of profit in the company or its associate companies, if any or reimbursement of any transaction or any other transaction of whatever nature with related parties.

The proviso to Section 188(1) also states that nothing in Section 188(1) will apply to any transaction entered into by the Company in the ordinary course of business and at arm’s length basis. Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 has also prescribed seeking of shareholders’ approval for material related party transactions.

The Company is inter alia engaged in the business of manufacturing, trading, import and export of pharmaceutical products. For the smooth functioning of the operations of the company, the company, from time to time, needs funds. Further, at times the excess funds are deployed in companies in which the Director(s) of the Company are interested. The deployments of funds in such companies are at an arm’s length basis. The Promoter Director of the Company and his associate companies had been infusing and intends to infuse funds and intends to involve in other transactions as are mentioned in Section 188(1) of the Companies Act, 2013

and Rules 15 and 16 of Companies (Meetings of Board and its Powers) Rules, 2014 that may become material in nature as these transactions are likely to exceed 10% of the net worth of the Company or may exceed the other perimeters/criteria's as are mentioned in applicable Rules under Companies (Meetings of Board and its Powers) Rules, 2014 and amendments thereto.

All the proposed transactions put up for approval are in the ordinary course of business and at arm's length. Pursuant to the provisions of Section 188(1) of the Companies Act, 2013 and applicable Rules made thereunder and the SEBI (Listing and Disclosure) Regulations, 2015, the following contracts/arrangements/transactions are material in nature and require the approval of the unrelated shareholders of the Company by way of Ordinary resolution:

Sr. No	Name of the Related Party	Relationship	Maximum Value of Transactions per annum with effect from April 01, 2018 (Rs. in lacs)
1	Mr. Peeyush Kumar Aggarwal	Director & Promoter of the Company	50.00*
2	Omkam Global Capital Pvt. Ltd.	Mr. Peeyush Kumar Aggarwal, Director & Promoter of the Company is also a Director & Promoter of Omkam Global Capital Pvt. Ltd.	800.00*
3	Omkam Developers Limited	Mr. Peeyush Kumar Aggarwal, Director & Promoter of the Company is also a Director & Promoter of Omkam Developers Limited.	600.00*

The annual value of the transactions proposed is estimated on the basis of the Company's current transactions and future business projections.

The members are further informed that members of the Company being a related party or having any interest in the resolution as set out in Item No. 4 shall abstain on voting on this resolution whether the entity is a related party to the particular transaction or not.

The Board of Directors recommends the resolution set forth in Item No. 4 for approval of the Member as an Ordinary Resolution.

Except Promoter Director and other related parties to the extent of their shareholding interest in the Company, no other Director or Key Managerial Personnel or their relatives are concerned or interested, financially or otherwise, in passing of this resolution.

For and on Behalf of the Board of Directors of Advik Laboratories Ltd.

**Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423**

Date **01st September, 2018**
Place: **New Delhi**

Director's Report

Dear Members,

Your Directors are delighted to present the 24th Annual Report of your Company together with the Audited Annual Accounts for the financial year ended 31st March, 2018.

1. Financial Results:

The Financial Performance of your Company for the year ended March 31, 2018 is summarized below

Particulars	(Amount in Lacs)	
	For the year ended	
	31.03.2018	31.03.2017
Revenue from operations	415.27	287.07
Profit/(Loss) before Depreciation & Income Tax	(46.87)	(685.39)
Less: Depreciation	58.82	59.03
Profit/(Loss) after depreciation	(105.69)	(744.42)
Less: Provision for Income Tax/Deferred Tax	(19.14)	(5.65)
Profit/(Loss) After Taxation	(86.55)	(738.76)
Other Comprehensive Income	1.61	1.42
Total Comprehensive Income for the period carried over to Reserve & Surplus a/c	(84.94)	(737.34)

2. Dividend:

In view of losses incurred by the Company, your Directors regret their inability to recommended dividend on equity shares for the year under review.

3. Reserves:

In view of insufficiency of profits, no amount is proposed to be transferred to Reserves for the year under review.

4. Brief description of the Company's working during the year:

During the year although total revenue of the Company increased by Rs. 128.20 Lacs as compare to previous year, but despite of best efforts by the management company has suffered loss of Rs. 105.69 lacs. The Board hopes to recover in the next financial year. Also company is in touch of some prominent supplier, who buys the goods on third party manufacturing process & export on their own. Company is also exploring South African market, where our products are well established

5. Change in the nature of business, if any:

During the year, there is no change in the nature of business activity of the company.

6. Material changes and commitments, if any, affecting the financial position of the company which has occurred between the end of the financial year of the company to which the financial statements relate and the date of the report:

During the period between the end of the financial year of the company and the date of the report, there are no material changes and commitments which affect the financial position of the company.

7. Details of significant and material orders passed by the Regulators or Courts or Tribunals impacting the going concern status and company's operations in future:

During the year, there is no significant and material orders passed by the Regulators or Courts or Tribunals which impact the going concern status and company's operations in future.

8. Details in respect of adequacy of internal financial controls with reference to the Financial Statements:

The Board has adopted policies and procedure for ensuring the orderly and efficient conduct of its business, including adherence to the company's policies, the safeguarding of its asset, the prevention and detection of fraud and error, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial disclosure.

9. Details of Subsidiary/Joint Ventures/Associate Companies:

The Company has no Subsidiary. During the year, no company has become or ceased as subsidiary/Joint-venture/Associate of the company.

10. Performance and financial position of each of the subsidiaries, associates and joint venture companies included in the consolidated financial statement:

During the year, no consolidated financial statements have been prepared by the company as the Company has no subsidiary company.

11. Public Deposits:

Your Company has not accepted any deposits from public within the meaning of Section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014, during the year under review. The details relating to deposits, covered under Chapter V of the Act is as under-

a)	accepted during the year	Nil
b)	remained unpaid or unclaimed as at the end of the year	Nil
c)	whether there has been any default in repayment of deposits or payment of interest thereon during the year and if so, number of such cases and the total amount involved	N.A. since the company has not accepted any deposits.
i.	at the beginning of the year	Nil
ii.	maximum during the year	Nil
iii.	at the end of the year	Nil

12. Auditors:

M/s. RMA & Associates LLP, Chartered Accountants, New Delhi, the Statutory Auditors of the Company (Registration No. 000978N/500062), had been appointed by the shareholders in the 19TH AGM held on 27.09.2013 from the conclusion of the said AGM till the conclusion of the 20TH AGM as per the provisions of the erstwhile Companies Act, 1956. Thereafter, they were appointed for four consecutive financial years, i.e. from the conclusion of the 20th AGM till the conclusion of the 24th AGM of the shareholders of the Company as per the provisions of Section 139(1) of the Companies Act, 2013. M/s. RMA & Associates, LLP, Chartered Accountants, New Delhi, the Statutory Auditors of the Company has completed the first term of five years as the Statutory Auditors of the Company.

As per the provisions of Section 139 of the Act, no listed company can appoint or re-appoint an audit firm as an auditor for more than two terms of five consecutive years. In view of the above, M/s. RMA & Associates, LLP, Chartered Accountants, New Delhi, being eligible for re-appointment and based on the recommendation of the Audit Committee, the Board of Directors has, at its meeting held on August 13, 2018, proposed the reappointment of M/s. RMA & Associates, LLP, Chartered Accountants, New Delhi, as the statutory auditors of the Company for a further term of five years to hold office from the conclusion of this AGM till the conclusion of the twenty-ninth AGM of the Company to be held in the year 2023.

The Company has received a certificate from the auditors confirming that they are eligible for appointment as auditors of the Company under Section 139 of the Companies Act, 2013 and meet the criteria for appointment specified in Section 141 of the Companies Act, 2013 and SEBI Listing Regulations, 2015.

Based on the recommendations of the Audit Committee and as per the provisions of Section 139(1) of the Companies Act, 2013 and Rules made thereunder, the Board of Directors of your Company proposes to reappoint M/s RMA & Associates, Chartered Accountants, as the Statutory Auditors of the Company from the F.Y. 2018-19 to F.Y. 2022-23.

COST AUDIT

Pursuant to the various circulars issued by the Ministry of Corporate Affairs, the Company is required to maintain cost records for all the products being manufactured by it and get the same audited by a cost auditor. But due to turnover based criteria as prescribed by Central Government, cost audit is not required on our company for the year 2018-19 as per notification no. F.No.1/40/2013-CL-V dated 31.12.2014.

13. Auditors' Report:

The company always strives to present a unqualified Financial Statement. However, there are some observations on Auditor's Report which are as under:-

a) Due to default in payments of bank loans, the company's accounts have been classified as Non-Performing Assets (NPA) by the bank. Indian Overseas Bank has not charged interest on Cash credit & Term Loan Limits. During the period under review no provision has been made for such interest in the books of account of the company and to that extent bank's loan liability and total loss is understated by Rs 398.16 lacs plus penal charges that the bank may charge.

b) Trade Receivables & Trade Payables are subject to confirmation, reconciliation, adjustments & provisions, if any which may arise out of confirmation and reconciliation.

c) The company had not determined the fair value of Investments in unquoted equity shares of other companies as per IND AS.

Report of the Statutory Auditor is annexed with the Annual Report, however, as regards qualifications' made by the Auditors' in their report your directors states as under:-

a) The Company's accounts had become Non Performing Assets (NPA) with Indian Overseas Bank and due to this reason, IOB has stopped charging interest from the company on its outstanding debts. In view of the above, the company has not charged to statement of Profit & Loss account Interest expenses of Rs. 398.16 Lacs in respect of delay of repayments of borrowings from the bank. However, company is making necessary efforts to reach One Time Settlement with Indian Overseas Bank & has already sent the One Time Settlement proposal with Indian Overseas Bank and the same is under consideration at the end of Indian Overseas Bank.

b) The Company has received some confirmations from its Debtors & Creditors & are in the process of obtaining the necessary confirmations from its remaining Trade Receivables & Trade Payables.

c) The company has misplaced/lost the share certificates of the Investment made by it in unquoted equity shares of other companies during the shifting of its records. Hence these share certificates are not physically held by the company. The Company has sent various request letters to the companies in which it has made investments for issue of duplicate share certificates. However, till date the company has not received any reply from these companies. In order to ensure the compliance of IND AS in true letter and spirits, the company is also trying to ascertain the fair market value of its investments.

14. Share Capital:

A	Issue of equity shares with differential rights:	During the year, company has not issued any equity shares with differential rights.
B	Issue of sweat equity shares	During the year, company has not issued any Sweat equity shares.
C	Issue of employee stock options	During the year, company has not issued employee stock options.
D	Provision of money by company for purchase of its own shares by employees or by trustees for the benefit of employees	Rs Nil
E	Bonus Shares	No bonus shares were issued during the year under review.

15. Extract of the annual return (MGT-9):

The extract of the annual return in Form No. MGT-9 is annexed herewith (**Annexure-1**).

16. Conservation of energy, technology absorption and foreign exchange earnings and outgo:

The Company lay focus on Conservation of energy with studies, discussions and analysis, which are undertaken regularly for further improvement. In terms of requirement of Section 134 (3) (a) of the Companies Act, 2013 read with rule 8 of the Companies (Accounts) Rules, 2014 the required information relating to conservation of energy, technology absorptions and foreign exchange earnings and outgo are Annexed hereto as **Annexure-2**.

17. Corporate Social Responsibility (CSR):

In terms of section 135(1) of the Companies Act, 2013, the provisions of Corporate Social Responsibility are not applicable to the Company.

18. Directors and Key Managerial Personnel:

A) Changes in Directors and Key Managerial Personnel

Retirement by Rotation

In accordance with the provisions of the Companies Act, 2013, Mr. Sachin Garg (DIN 03320351), Managing Director of the Company, retires by rotation at the forthcoming AGM, and being eligible, offers himself for re-appointment.

Considering the background and experience of Mr. Sachin Garg, the Board is of the opinion that his reappointment will immensely benefit your Company. The Board recommends his reappointment.

Brief profile of the Mr. Sachin Garg, Director of the Company who is proposed to be re-appointed is mentioned herein below:

Mr. Sachin Garg, aged 38 years, is a fellow Member of the Institute of Chartered Accountants of India. He has rich experience of more than 10 years. He has significant expertise in Corporate Laws, Audit, Finance, Accounts & Taxation, Capital Markets, Project Management etc. He has always demonstrated a certain dynamism and foresight seen in the most pragmatic of professional.

Details of his other Directorships and Committee Memberships are as follows:

Sl. No.	Directorships in other Public Companies	Committee Membership/Chairmanship	
1	Onus Plantations and Agro Limited	Nil	Nil
2	Onshore Shipping Limited	Nil	Nil

Mr. Sachin Garg does not hold any shareholding in the Company. Mr. Sachin Garg is also not related to any of the Directors of the Company.

B. Appointment and Cessation:

There is no appointment or cessation of Directors during the year under review.

C. Declaration by Independent Directors:

Your Company has received necessary declaration from each Independent Director of the Company under Section 149(6) of the Companies Act, 2013 read with Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming that they meet with the criteria of independence as prescribed under the aforesaid Section and Regulation.

D. Formal Annual Evaluation:

In compliance with the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, during the year, the Board adopted a formal mechanism for evaluating its performance as well as that of its Committees and Individual Directors including the Chairman of the Board. Structured questionnaires were used in the overall Board evaluation comprising various aspects of Board function.

The evaluation of Independent Directors was carried out by the entire Board and that of the Chairman and Non – Independent Directors were carried out by the Independent Directors.

The Directors were satisfied with the evaluation results, which reflected the overall engagement of the Board and its Committees with the Company.

19. Number of meetings of the Board of Directors:

Eight meetings of the Board of Directors were held during the year on 30th May, 2017, 20th June, 2017, 02nd September, 2017, 14th September, 2017, 14th December, 2017, 01st February, 2018, 14th February, 2018 and 01st March, 2018.

A separate meeting of the Independent Directors was held on 01.03.2018.

20. Committees of the Board:

During the year under, in accordance with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board reconstituted some of its Committees. The Committees are as follows:

- * Audit Committee
- * Stakeholders' Relationship Committee
- * Nomination and Remuneration Committee
- * Risk Management Committee

Details of the said Committees alongwith their charters, compositions and meetings held during the year are provided in the Report of Corporate Governance as a part of this Annual Report.

21. Board Evaluation:

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, mandates that the Board shall monitor and review the Board Evaluation framework. The Companies Act, 2013 provides that a formal annual evaluation needs to be made by the Board of its own performance and that of its Committees and individual directors. Schedule IV of the Companies Act, 2013, states that the performance evaluation of Independent Directors shall be done by the entire Board of Directors, excluding the director being evaluated.

The Board of Directors has carried out an annual evaluation of its own performance, Board Committees and individual directors pursuant to the provisions of the Companies Act, 2013 and the corporate governance requirements as prescribed by Securities and Exchange Board of India ("SEBI") under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Structured questionnaires were used in the overall Board evaluation comprising various aspects of Board function.

The performance of the Board was evaluated by the Board on the basis of Performance Evaluation Policy formulated by the Board and after seeking inputs from all the directors on the basis of the criteria such as the Board composition and structure, effectiveness of board processes, information and functioning, etc.

The performance of the Committees was evaluated by the Board after seeking inputs from the Committee members on the basis of the criteria such as the composition of committees, effectiveness of Committee meetings, etc. and on such further criteria as is set out in the Performance Evaluation Policy (**as per Annexure -3**) formulated by the Nomination and Remuneration Committee and approved by the Board to evaluate the performance of the Board and its Committees.

The Board and the Nomination and Remuneration Committee ("NRC") reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the Board and Committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc. In addition, the Chairman was also evaluated on the key aspects of his role.

In a separate meeting of Independent Directors held on 01.03.2018, performance of non-Independent Directors, performance of the board as a whole and performance of the Chairman was evaluated, taking into account the views of executive directors and non-executive directors. The same was discussed in the board meeting that followed the meeting of the Independent Directors, at which the performance of the Board, its committees and individual directors was also discussed.

Based on the outcome of performance evaluation for the financial year 2017-18, further measures/actions have been suggested to improve and strengthen the effectiveness of the Board and its Committees.

22. Policy on Directors' Appointment and Remuneration:

Your Company has a policy to have an appropriate mix of executive and independent directors to maintain the independence of the Board, and separate its functions of governance and management. As on March 31, 2018, the Board consisted of 4 members and out of which 1 (One) is an Executive Director, 2 are Non Executive Independent Directors including 1 Woman Director and 1 is a Non-Executive, Promoter Director.

The policy of the Company on directors' appointment and remuneration, including criteria for determining qualifications, positive attributes, independence of a Director, and other matters provided under sub-section (3) of Section 178 of the Companies Act, 2013, of the Companies Act, 2013, adopted by the Board, is attached as **Annexure – 4** to the Board Report. Further the remuneration paid to the Directors is as per the terms laid out in the nomination and remuneration policy of the Company.

23. Risk management policy and Internal Control:

The Company has adopted a Risk Management Policy duly approved by the Board and also has in place a mechanism to identify access, monitor and mitigate various risks to key business objectives. Major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis.

24. Whistle Blower Policy and Vigil Mechanism:

Your Company has established a "Whistle Blower Policy" and Vigil Mechanism for directors and employees to report to the appropriate authorities concerns about the unethical behavior actual or suspected, fraud or violation of the Company's code of conduct policy and provides safeguards against victimization of employees who avail the mechanism and also provide for direct access to the Chairman of the Audit Committee. The said policy has been uploaded on the website of the company. The same can be accessed at the website of the Company under the Investment Information head at the link http://www.advikindia.com/reports/policy/whistle_blower.pdf.

25. Particulars of loans, guarantees or investments under Section 186:

Particulars and details of loans given, investments made or guarantees given and securities provided, if any, are given in the Notes to the Financial Statements.

26. Contracts and arrangements with related parties:

The policy on Related Party Transactions as approved by the Board is uploaded on the Company's website http://www.advikindia.com/reports/policy/related_party.pdf. Pursuant to Section 134 (3)(h) of the Companies Act, 2013 and Rules made there under, particulars of transactions with related parties as required under section 188(1) of the Companies Act, 2013 are mentioned in the prescribed Form AOC-2 which is annexed herewith as "**Annexure-5**". The details of the transactions with related parties are provided in Notes to Financial Statements.

27. Secretarial Audit Report:

In terms of Section 204(1) of the Companies Act, 2013 and the rules made thereunder, M/s Kundan Agrawal & Associates was appointed as the Secretarial Auditor to undertake the Secretarial Audit of the Company for the F.Y. 2017-18. The report of the Secretarial Audit in Form MR -3 is annexed to and forms part of this Report as per **Annexure –6**

There are no qualifications, reservations, adverse remarks or disclaimers given by the Secretarial Auditor in the Report.

28. Corporate Governance:

Your Company has been benchmarking itself with well-established Corporate Governance practices besides strictly complying with the requirements of Regulation 17 to 27 and any other applicable Regulation of the SEBI under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

A separate "Report on Corporate Governance" together with requisite certificate obtained from Statutory Auditors of the Company, confirming compliance with the provisions of Corporate Governance as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is annexed to this Report.

29. Directors' Responsibility Statement:

Pursuant to Section 134(3)(c) read with 134(5) of the Companies Act, 2013, the Board of Directors to the best of their knowledge and belief confirm that:

- (a) in the preparation of the annual accounts for the financial year ended 31st March, 2018, the applicable accounting standards had been followed and no material departures have been made from the same;
- (b) the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year i.e. on 31st March, 2018 and of the profit or loss of the company for that period;
- (c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) the directors have prepared the annual accounts on a going concern basis;
- (e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and operating efficiently; and
- (f) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

30. Particulars of Employees:

There are no employees employed throughout the financial year who were in receipt of remuneration of Rs. 102 Lacs or more or employed for part of the year who were in receipt of remuneration of Rs. 8.50 lacs or more a month under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Remuneration) Rules, 2014.

Disclosure u/s 197(12) and Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are annexed herewith as **Annexure – 7**.

During the year under review, none of the Directors of the Company has received remuneration from the Company.

The Nomination and Remuneration Committee of the Company has affirmed in its meeting held on 01/03/2018 that the remuneration paid to the Senior Management Employee/KMPs is as per the remuneration policy of the Company

31. Internal Auditors & Their Report:

Pursuant to the provisions of Section 138 of the Companies Act, 2013 and Rules made thereunder, the Company had appointed M/s Sanghi & Co. as Internal Auditor for the financial year 2017-18.

Internal Financial Control and Their Adequacy

The Board has adopted policies and procedure for ensuring the orderly and efficient conduct of its business, including adherence to the company's policies, the safeguarding of its asset, the prevention and detection of fraud and error, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial disclosure.

The Company has an adequate internal controls system commensurate with its size and the nature of its business. All the transactions entered into by the Company are duly authorized and recorded correctly. All operating parameters are monitored and controlled. The top management and the Audit Committee of the Board of Directors review the adequacy and effectiveness of internal control systems from time to time

32. Disclosures under Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013 read with Rules thereunder:

Pursuant to the provisions of Section 22 of Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013 read with Rules thereunder, the Company has not received any complaint of sexual harassment during the year under review.

33. Reporting of Frauds by Auditors'

During the year under review, the Statutory Auditors and the Secretarial Auditor have not reported any instances of frauds committed in the Company by its Officers or Employees to the Audit Committee under Section 143(12) of the Companies Act, 2013, details of which need to be mentioned in this Report.

34. Secretarial Standards

The Company has complied with the provisions of the applicable Secretarial Standards, i.e. SS-1 (Secretarial Standard on Meetings of the Board of Directors) and SS-2 (Secretarial Standard on General Meetings).

35. Human Resources:

Your Company treats its "human resources" as one of its most important assets. We focus on all aspects of the employee lifecycle. This provides holistic experience for the employees as well. During their tenure at the Company, employees are motivated through various skill development programs. We create effective dialogue through our communication channels to ensure effective dialogue through our communication channels to ensure that feedback reach the relevant team, including leadership.

Your Company continuously invests in attraction, retention and development of talent on an ongoing basis. A number of programs that provide focused people attention are currently underway. Your Company thrust is on the promotion of talent internally through job rotation and job enlargement.

36. Segment-wise performance:

The Company is into single reportable segment only.

37. Management Discussion and Analysis:

The Management Discussion and Analysis Report on the business of the Company and performance review for the year ended March 31, 2018, as stipulated in Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is presented in a separate report which forms part of the Report.

36. Acknowledgements:

Your Directors are grateful to the Government of India, the Reserve Bank of India, the Securities and Exchange Board of India, the Stock Exchanges and other regulatory authorities for their valuable guidance and support and wish to express their sincere appreciation for their continues co-operation and assistance. We look forward for their continued support in future.

Your directors would like to express their sincere appreciation for the assistance and cooperation received from banks, customers, vendors, Government, members and employees during the year under review.

Finally, the Directors thank you for your continued trust and support.

**For and on Behalf of the Board of Directors of
Advik Laboratories Ltd.**

**Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423**

**Date 01st September, 2018
Place: New Delhi**

MANAGEMENT DISCUSSION AND ANALYSIS REPORT**INDUSTRY STRUCTURE AND DEVELOPMENT**

India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in UK. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms.

Market Size

The pharmaceutical sector was valued at US\$ 33 billion in 2017. The country's pharmaceutical industry is expected to expand at a CAGR of 22.4 per cent over 2015–20 to reach US\$ 55 billion. India's pharmaceutical exports stood at US\$ 17.27 billion in 2017-18 and are expected to reach US\$ 20 billion by 2020.

Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug Administration (USFDA) in 2017. The country accounts for around 30 per cent (by volume) and about 10 per cent (value) in the US\$ 70-80 billion US generics market.

India's biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry and bioinformatics is expected grow at an average growth rate of around 30 per cent a year and reach US\$ 100 billion by 2025. Biopharma, comprising vaccines, therapeutics and diagnostics, is the largest sub-sector contributing nearly 62 per cent of the total revenues at Rs 12,600 crore (US\$ 1.89 billion).

Investments

The Union Cabinet has given its nod for the amendment of the existing Foreign Direct Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100 per cent under the automatic route for manufacturing of medical devices subject to certain conditions.

The drugs and pharmaceuticals sector attracted cumulative FDI inflows worth US\$ 15.59 billion between April 2000 and December 2017, according to data released by the Department of Industrial Policy and Promotion (DIPP).

Some of the recent developments/investments in the Indian pharmaceutical sector are as follows:

- In 2017, Indian pharmaceutical sector witnessed 46 merger & acquisition (M&A) deals worth US\$ 1.47 billion.
- The exports of Indian pharmaceutical industry to the US will get a boost, as branded drugs worth US\$ 55 billion will become off-patent during 2017-2019.

The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value. Branded generics dominate the pharmaceuticals market, constituting nearly 70 to 80 per cent of the market. India is the largest provider of generic drugs globally with the Indian generics accounting for 20 per cent of global exports in terms of volume. Of late, consolidation has become an important characteristic of the Indian pharmaceutical market as the industry is highly fragmented.

India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms.

The UN-backed Medicines Patent Pool has signed six sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs, allowing them to make generic anti-AIDS medicine Tenofovir Alafenamide (TAF) for 112 developing countries. Owing to robust historical growth and future prospects, many MNC companies have active presence in the Indian pharma space.

Besides the domestic market, Indian pharma companies also have a large chunk of their revenues coming from exports. Major companies are focusing on the generics market in the US, Europe and semi-regulated markets; others are focusing on custom

manufacturing for innovator companies. Biopharmaceuticals is also increasingly becoming an area of interest given the complexity in manufacture and limited competition.

India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level.

Pharmaceutical Sector Overview

Global

The pharmaceutical industry plays a unique role in improving the lives of patients. It is also one of the world's fastest growing industries and among the biggest contributors to the world economy.

Global spending

According to the Quintiles IMS Institute, the pharmaceutical market will reach nearly USD 1,485 billion by 2021, an increase of USD 350-380 billion from the USD 1,105 billion recorded in 2016. This growth is expected to be driven by market expansion in pharmerging countries and a higher proportion of aged population in developed countries.

The Indian pharmaceutical industry is the 14th largest market in the world by value; in terms of volume it is the 3rd largest. India manufactures 20% of all generics made globally and exports to 200 countries, with USA as the principal market. While during the year under review, domestic growth slowed down in the wake of implementation of Goods and Services Tax (GST), the outlook remains positive. Increase in the size of middle-class households coupled with the improvement in medical infrastructure and jump in the penetration of health insurance in the country are expected to boost domestic demand for pharmaceutical products. By 2020, India is anticipated to become the top three pharmaceutical markets by incremental growth and 6th largest market globally in absolute size. India's focus on providing complex and speciality products, customercentricity, regulatory compliance, quality improvement and operational efficiency are expected to enhance exports. Exports from India stood at USD 16.84 billion in FY 2016-17; it is expected to reach USD 20 billion by 2020. 20 In Pursuit of Excell

The Indian pharmaceutical industry is well-positioned to reinforce its position as a global pharmaceutical provider. As per industry estimates, India's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015-20 to reach USD 55 billion and by 2025 to grow to USD 100 billion.

FACTORS INFLUENCING GROWTH OF THE INDUSTRY

The Indian pharmaceutical industry ranks 14th in the world by value of pharmaceutical products. With a well-established domestic manufacturing base and low-cost skilled manpower, India is emerging as a global hub for pharma products and the industry continues to be on a growth trajectory. Moreover, India is significantly ahead in providing chemistry services such as analogue preparation, analytical chemistry, and structural drug design, thereby offering ample scope in contract research and other emerging segments in the pharmaceutical industry. Some of the major factors that would drive growth in the industry are as follows:

- **Increase in domestic demand:** More than half of India's population does not have access to advanced medical services and depend on traditional medicine practices. However, with increase in awareness levels, rising per capita income, change in lifestyle due to urbanization, and increase in literacy levels, demand for advanced medical treatment is expected to rise. Moreover, growth in the middle-class population would further influence demand for pharmaceutical products.
- **Rise in outsourcing activities:** Increase in the outsourcing business to India would also drive growth of the Indian pharmaceutical industry. Some of the factors that are likely to influence clinical data management and bio-statistics markets in India in the near future include: 1) its cost efficient research vis-à-vis other countries 2) highly-skilled labour base 3) cheaper cost of skilled labour 4) presence in end-to-end solutions across the drug-development spectrum and 5) robust growth in the IT industry.
- **Growth in healthcare financing products:** Development in the Indian financial industry has eased healthcare financing with products such as health insurance policy becoming popular. This has resulted in increase in healthcare spending, which in turn, has benefitted the pharmaceutical industry.
- **Demand from emerging segments:** Some of the emerging segments such as contract research and development, bio-pharma, clinical trials, bio-generics, medical tourism, and pharma packaging are also expected to drive growth of the Indian pharmaceutical industry.

SWOT ANALYSIS OF THE INDUSTRY

The SWOT analysis of the industry reveals the position of the Indian pharmaceutical industry in respect to its internal and external environment.

a) **STRENGTHS**

In India the cost of manufacturing pharma products are less and effective comparing to other countries. India has a strong manufacturing base. Due to the technology development the high skilled work force is available in India. The marketing and distribution system is also on the higher side in India by communication development. The diverse ecosystem also strengthens the sector.

- Higher GDP growth leading to increased disposable income in the hands of general public and their positive attitude towards spending on healthcare.
- Low-cost, highly skilled set of English speaking labour force and proven track record in design of high technology manufacturing devices.
- Growing treatment naive patient population.
- Low cost of innovation, manufacturing and operations.

b) **WEAKNESSES**

Even though the FDI limit is liberalized there is still less investment in research and development which has to be taken care of by the Industry and the government. The lack of co-ordination between the industry and academician is on the weak point. When comparing to other expenditures by households the expenditure incurred on health care is negligible. The manufacture of low and fake medicines which are having low quality is a threatening to this industry

- Stringent pricing regulations affecting the profitability of pharma companies.
- Poor all-round infrastructure is a major challenge.
- Presence of more un-organised players versus the organised ones, resulting in an increasingly competitive environment, characterised by stiff price competition.
- Poor health insurance coverage.

c) **OPPORTUNITIES**

Despite the weaknesses of the industry the growth of this industry is expected greatly because there is increased export potential. It is also expected that the export of generic drugs to the developed markets will be on the increase. There is immense scope to position India as a centre for international clinical trials. It is also expected that India will be a key player in global pharmaceutical R&D.

- Global demand for generics rising.
- Rapid OTC and generic market growth.
- Increased penetration in the non - metro markets.
- Large demand for quality diagnostic services.
- Significant investment from MNCs.
- Public-Private Partnerships for strengthening Infrastructure.
- Opening of the health insurance sector and increase in per capita income - the growth drivers for the pharmaceutical industry.
- India, a potentially preferred global outsourcing hub for pharmaceutical products due to low cost of skilled labour.

d) **THREATS / RISKS AND CONCERNS**

The product patent regime is one of the major threats to domestic Industry. To face this threat the industry is taking up R&D initiative aggressively. The Drug Price Control order made by the Government of India put undue pressure on product prices which affects the profitability of the pharmaceutical companies. The new MRP based excise duty regime is the threat for the small business companies.

- Wage inflation.
- Government expanding the umbrella of the Drugs Price Control Order (DPCO).
- Other low-cost countries such as China and Israel affecting outsourcing demand for Indian pharmaceutical products
- Entry of foreign players (well-equipped technology-based products) into the Indian market.

GOVERNMENT INITIATIVES

The implementation of the Goods and Services Tax (GST) is expected to be a game-changer for the Indian Pharmaceuticals industry. It will lead to tax-neutral inter-state transactions between two dealers, thereby reducing the dependency on multiple states and increasing the focus on regional hubs. It is expected to result in an efficient supply chain management, which is expected to reduce its cost considerably. The cost of technology and investment is expected to reduce on account of tax credit which can be availed now on the duties levied on import of costly machinery and equipment.

Some of the initiatives taken by the government to promote the pharmaceutical sector in India are as follows:

- The National Health Protection Scheme is largest government funded healthcare programme in the world, which is expected to benefit 100 million poor families in the country by providing a cover of up to Rs 5 lakh (US\$ 7,723.2) per family per year for secondary and tertiary care hospitalisation. The programme was announced in Union Budget 2018-19.
- In March 2018, the Drug Controller General of India (DCGI) announced its plans to start a single-window facility to provide consents, approvals and other information. The move is aimed at giving a push to the Make in India initiative.
- The Government of India is planning to set up an electronic platform to regulate online pharmacies under a new policy, in order to stop any misuse due to easy availability.
- The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacture. Approval time for new facilities has been reduced to boost investments.
- The government introduced mechanisms such as the Drug Price Control Order and the National Pharmaceutical Pricing Authority to deal with the issue of affordability and availability of medicines.

ROAD AHEAD

Medicine spending in India is expected to increase at 9-12 per cent CAGR between 2018-22 to US\$ 26-30 billion, driven by increasing consumer spending, rapid urbanisation, and raising healthcare insurance among others.

Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers that are on the rise.

The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.

The Indian pharmaceutical market size is expected to grow to US\$ 100 billion by 2025, driven by increasing consumer spending, rapid urbanisation, and raising healthcare insurance among others.

Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers that are on the rise.

The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.

OUTLOOK

Overall growth outlook for the Indian drugs and pharmaceutical industry appears positive. Pharma manufacturers are likely to benefit from rise in demand for generic products. Some of the factors that would drive growth in the domestic pharma industry are:

- 1) low cost operations
- 2) research-based processes
- 3) improvements in API and,
- 4) availability of skilled manpower.

The domestic formulations and bulk drugs markets are currently facing price pressure as benefits of cheaper drugs have been shifted to end-users and trade channels. Hence, consolidation, partnership and alliances are expected to gather momentum in the near future. Off patenting of branded drugs would increase demand for generic drugs. This provides immense opportunities to the Indian pharmaceutical companies especially given their prior experience in generic drug development. Some other factors such as high penetration in the global markets and increase of share in Abbreviated New Drug Application (ANDA) filings are likely to power growth of the formulations market. Major growth drivers for the Indian bulk drug industry include rise in demand for contract manufacturing, increase of share in Drug Master Files (DMF) filings and process innovation.

SEGMENT WISE PERFORMANCE

The Company is into single reportable segment only.

INTERNAL CONTROL SYSTEM

The Company has laid down internal financial controls to be followed by the Company and such policies and procedures adopted by the Company for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information.

The Company has also laid down an adequate system for legal compliances. It has created appropriate structures with proper delegations of duties and responsibilities of employees at each level on enterprise basis which ensures the proper adherence and compliance of such systems.

Both the Internal Financial Control and Enterprise Legal Compliance System are subject to review by the Management in respect of their adequacy and operative effectiveness which in turn are also reviewed by the Internal Auditors, Statutory Auditors and Audit Committee. Finally, the Board of Directors of the Company also review and take note of them.

HUMAN RESOURCES

Human resource is considered as key to the future growth strategy of the Company and looks upon to focus its efforts to further align human resource policies and processes to meet its business needs. The Company aims to develop the potential of every individual associated with the Company as a part of its business goal. Respecting the experienced and mentoring the young talent has been the bedrock for the Company's growth.

Human resources are the principal drivers of change. They push the levers that take futuristic businesses to the next level of excellence and achievement.

CAUTIONARY STATEMENT

Investors are cautioned that this discussion contains statements that involve risks and uncertainties. Words like anticipate, believe, estimate intend, will, expect and other similar expressions are intended to identify "Forward Looking Statements". The company assumes no responsibility to amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events. Actual results could differ materially from those expressed or implied. Important factors that could make the difference to the Company's operations include cyclical demand and pricing in the Company's principal markets, changes in Government Regulations, tax regimes, economic developments within India and other incidental factors.

For and on Behalf of the Board of Directors of Advik Laboratories Ltd.

**Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423**

**Date : 01st September, 2018
Place: New Delhi**

Annexure - 1

FORM NO. MGT 9

EXTRACT OF ANNUAL RETURN

As on financial year ended on 31.03.2018

Pursuant to Section 92 (3) of the Companies Act, 2013 and Rule 12(1) of the Company (Management & Administration) Rules, 2014.

I.REGISTRATION & OTHER DETAILS:

1.	CIN	L74899HR1994PLC038300
2.	Registration Date	09/09/1994
3.	Name of the Company	Advik Laboratories Limited
4.	Category/Sub-category of the Company	Company Limited by Shares/Indian Non- Government Company
5.	Address of the Registered office & contact details	138, Roz Ka-Meo Industrial, Sohna Distt. Mewat, Haryana – 122103 Tel nos. : 0124-2362471, 09813179885
6.	Whether listed company	Yes
7.	Name, Address & contact details of the Registrar & Transfer Agent, if any.	M/s. MAS Services Limited T-34, 2 nd Floor, Okhla Industrial Area, Phase-II, New Delhi-110020 011-26387281-83

II.PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All the business activities contributing 10 % or more of the total turnover of the company are as given below :

S. No.	Name & Description of main products	NIC Code of the product	% to total turnover of the Company
1.	Pharmaceuticals Products	24232	100%

III.PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES: NOT APPLICABLE

Sl. No.	Name and Address of the Company	CIN/GLN	Holding/Subsidiary/ Associate	% of Shares Held
--	--	--	--	--

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year[As on 1st-April-2017]				No. of Shares held at the end of the year[As on 31-March-2018]				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual/ HUF	1957159	-	1957159	10.24	1957159	-	1957159	10.24	-
b) Central Govt.	-	-	-	-	-	-	-	-	-
c) State Govt.(s)	-	-	-	-	-	-	-	-	-
d) Bodies Corp.	4902322	-	4902322	25.65	4902322	-	4902322	25.65	-
e) Banks / FI	-	-	-	-	-	-	-	-	-
f) Any other	-	-	-	-	-	-	-	-	-
Sub-total(A)(1):-	6859481	-	6859481	35.89	6859481	-	6859481	35.89	-
(2) Foreign									

a) NRIs- Individual	-	-	-	-	-	-	-	-	-
b) Other- Individuals	-	-	-	-	-	-	-	-	-
c) Bodies Corporate	-	-	-	-	-	-	-	-	-
d) Banks/FI	-	-	-	-	-	-	-	-	-
e) Any Other	-	-	-	-	-	-	-	-	-
Sub-total (A)(2):-	-	-	-	-	-	-	-	-	-
Total shareholding of Promoter (A)=(A)(1)+(A)(2)	6859481	-	6859481	35.89	6859481	-	6859481	35.89	-
B. Public Shareholding									
1. Institutions									
a) Mutual Funds	-	-	-	-	-	-	-	-	-
b) Banks / FI	-	-	-	-	-	-	-	-	-
c) Central Govt.	-	-	-	-	-	-	-	-	-
d) State Govt.(s)	-	-	-	-	-	-	-	-	-
e) Venture Capital Funds	-	-	-	-	-	-	-	-	-
f) Insurance Companies									
g) FIs	-	-	-	-	-	-	-	-	-
h) Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i) Others (specify)	-	-	-	-	-	-	-	-	-
Sub-total (B)(1):-	-	-	-	-	-	-	-	-	-
2. Non-Institutions									
a) Bodies Corp.									
i) Indian	6116592	-	6116592	32.00	5974127	-	5974127	31.26	(0.74)
ii) Overseas	-	-	-	-	-	-	-	-	-
b) Individuals									
i) Individual shareholders holding nominal share capital up to Rs. 1 lakh	3317203	11280	3328483	17.42	3414284	12780	3427064	17.93	0.51
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	2603202	-	2603202	13.62	2688097	-	2688097	14.07	0.45
NBFC Registered with RBI	-	-	-	-	110280	-	110280	0.58	0.58
c) Others (specify)									

Non Resident Indians	16902	-	16902	0.09	16167	-	16167	0.08	(0.01)
Hindu Undivided Family	182201	-	182201	0.95	-	-	-	-	(0.95)
Clearing Members	4539	-	4539	0.02	36184	-	36184	0.18	0.16
Sub-total (B)(2):-	12240639	11280	12251919	64.11	12239139	12780	12251919	64.11	-
Total Public Shareholding (B)=(B)(1)+(B)(2)	12240639	11280	12251919	64.11	12239139	12780	12251919	64.11	-
C. Shares held by Custodian for GDRs & ADRs	-	-	-	-	-	-	-	-	-
Grand Total (A+B+C)	19100120	11280	19111400	100.00	19098620	12780	19111400	100.00	-

II) Shareholding of Promoter-

S no.	Shareholder's Name	Shareholding at the beginning of the year [As on 1st-April-2017]			Shareholding at the end of the year [As on 31st-March-2018]			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1	Omkam Pharmaceuticals Pvt. Ltd.	4902322	25.65	-	4902322	25.65	3781147	-
2	Peeyush Kumar Aggarwal	1957159	10.24	-	1957159	10.24	-	-
	Total	6859481	35.89	-	6859481	35.89	3781147	-

iii) Change in Promoters' Shareholding (please specify, if there is no change):

Sl. No.	Particulars	Shareholding at the beginning of the year [As on 1st-April-2017]		Date	Increase/ Decrease in Shareholding	Reason	Cumulative Shareholding during the Year (1st-April-2017 to 31st-March, 2018)	
		No. of shares	% of total shares of the company				No. of shares	% of total shares of the company
1.M/s. Omkam Pharmaceuticals Private Limited								
	At the beginning of the year	4902322	25.65					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the end of the year	4902322	25.65	Nil	Nil	Nil	4902322	25.65

2. Mr. Peeyush Kumar Aggarwal								
	At the beginning of the year	1957159	10.24					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the end of the year	1957159	10.24	Nil	Nil	Nil	1957159	10.24

iv) Shareholding Pattern of top ten Shareholders:
(Other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.	For Each of the Top 10 Shareholders	Shareholding at the beginning of the year [As on 1st-April-2017]		Date	Increase/ Decrease in Shareholding	Reason	Cumulative Shareholding during the Year (1st-April-2017 to 31st-March, 2018)	
		No. of shares	% of total shares of the company				No. of shares	% of total shares of the company
1.M/s. Pataliputra International Limited								
	At the beginning of the year	2629000	13.76					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the end of the year	--	--	--	--	--	2629000	13.76
2. M/s. Dhiru Builders And Promoters Pvt. Ltd.								
	At the beginning of the year	2605270	13.63					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the end of the year	--	--	--	--	--	2605270	13.63
3. Mr. Subramanian P								
	At the beginning of the year	1282992	6.71					
	Date wise Increase / Decrease in Shareholding during the year specifying	Nil	Nil	Nil	Nil	Nil	Nil	Nil

	the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)							
	At the end of the year	--	--	--	--	--	1282992	6.71
4. M/s Zuber Trading								
	At the beginning of the year	22624	0.12					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)			07.04.17 19.05.17 26.05.17 30.05.17	24000 57565 211859 (94500)	Purchase Purchase Purchase Sale	46624 104189 316048 221548	0.24 0.55 1.65 1.16
	At the end of the year	--	--	--	--	--	221548	1.16
5. M/s. Sampark Securities Pvt. Ltd.								
	At the beginning of the year	203229	1.06					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the end of the year	--	--	--	--	--	203229	1.06
6. Ms. Pinky Sachdeva								
	At the beginning of the year	161150	0.84					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the end of the year	--	--	--	--	--	161150	0.84
7. M/s. Shanthi General Finance P Limited								
	At the beginning of the year	110280	0.58					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/	Nil	Nil	Nil	Nil	Nil	Nil	Nil

	sweat equity etc.)							
	At the end of the year	--	--	--	--	--	110280	0.58
8. M/s. Indivar Traders Private Limited								
	At the beginning of the year	Nil	Nil					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	94500	Purchase	94500	0.49
	At the end of the year	--	--	--	--	--	94500	0.49
9. Mr. Santosh Pradeep Bohra								
	At the beginning of the year	92100	0.48					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the end of the year	--	--	--	--	--	92100	0.48
10. Mr. Vineet Chawla								
	At the beginning of the year	85000	0.44					
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the end of the year	--	--	--	--	--	85000	0.44

V) Shareholding of Directors and Key Managerial Personnel:

Sl. No.	Shareholding of each Directors and each Key Managerial Personnel*	Shareholding at the beginning of the year [As on 1st-April-2017]		Date	Increase/ Decrease in Shareholding	Reason	Cumulative Shareholding during the Year (1st-April-2017 to 31st-March, 2018)	
		No. of shares	% of total shares of the company				No. of shares	% of total shares of the company
1.Mr. Peeyush Kumar Aggarwal (Director)								
	At the beginning of the year	1957159	10.24					

Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
At the end of the year	--	--	--	--	--	--	1957159	10.24
2. Mr. Manoj Kumar Bhatia (Key Managerial Personnel)								
At the beginning of the year	450	0.00						
Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
At the end of the year	--	--	--	--	--	--	450	0.00

No other Directors/KMP holds Shares in the Company as on 31.03.2018.

V) INDEBTEDNESS -Indebtedness of the Company including interest outstanding/accrued but not due for payment.

Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	66450743	0	0	66450743
ii) Interest due but not paid	6158577	0	0	6158577
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	72609320	0	0	72609320
Change in Indebtedness during the financial year				
* Addition	0			0
* Reduction	0	0	0	0
Net Change	0	0	0	0
Indebtedness at the end of the fin. year				
i) Principal Amount	66450743	0	0	66450743
ii) Interest due but not paid	6158577	0	0	6158577
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	72609320*	0	0	72609320*

* Due to NPA of company accounts with IOB, Bank has not booked any interest on borrowings; accordingly company has not debited any interest in the book of accounts, during the year.

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL-

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl. No.	Particulars of Remuneration	Name of MD/WTD/ Manager				Total Amt.
		----	---	----	---	
1	Gross salary	----	---	----	---	----
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	----	---	----	---	----

	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	----	---	---	---	----
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	----	---	---	---	----
2	Stock Option	----	---	---	---	----
3	Sweat Equity	----	---	---	---	----
4	Commission - as % of profit & others	----	---	---	---	----
5	Others, please specify	----	---	---	---	----
	Total (A)	----	---	---	---	----
	Ceiling as per the Act	----	---	---	---	----

B. Remuneration to other directors

Sl. No.	Particulars of Remuneration	Name of Directors				Total Amount
1	Independent Directors	----	---	---	---	----
	Fee for attending board committee meetings	----	---	---	---	----
	Commission	----	---	---	---	----
	Others, please specify	----	---	---	---	----
	Total (1)	----	---	---	---	----
2	Other Non-Executive Directors	----	---	---	---	----
	Fee for attending board committee meetings	----	---	---	---	----
	Commission	----	---	---	---	----
	Others, please specify	----	---	---	---	----
	Total (2)	----	---	---	---	----
	Total (B)=(1+2)	----	---	---	---	----
	Total Managerial Remuneration	----	---	---	---	----
	Overall Ceiling as per the Act	----	---	---	---	----

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

Sl. No.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	CS	CFO	Total
1	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	0	260293	462000	722293
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0	0	0	0
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	0	0	0	0
2	Stock Option	0	0	0	0
3	Sweat Equity	0	0	0	0
4	Commission	0	0	0	0
	- as % of profit	0	0	0	0
	others, specify...	0	0	0	0
5	Others, please specify	0	0	0	0
	Total	0	260293	462000	722293

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)

A. COMPANY	
Penalty	NIL
Punishment	
Compounding	
B. DIRECTORS	
Penalty	NIL
Punishment	
Compounding	
C. OTHER OFFICERS IN DEFAULT	
Penalty	NIL
Punishment	
Compounding	

For and on Behalf of the Board of Directors of
Advik Laboratories Ltd.

Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423

Date: 01st September, 2018
Place: New Delhi

ANNEXURE "2" TO THE DIRECTOR'S REPORT

Information regarding Conservation of Energy, Technology Absorption and Foreign Exchange earnings & Outgo pursuant to Companies (Disclosures of Particulars in the Report of Board of Directors) Rules, 1988, forming part of Directors Report.

		Current Year	Previous Year
		2017-2018	2016-2017
A) CONSERVATION OF ENERGY			
I) Power and Fuel Consumption			
1) Electricity			
a)Purchased Unit (kwh)		98376	171886
Total amount		1045184	1848853
Rate/ Unit (Rs/Kwh)		10.62	10.76
b)Own generation			
i)Through Diesel			
Generator Unit (Kwh)		5280	10800
Unit per litre of Diesel oil (Kwh)		2.40	2.70
Cost/Unit (Rs/ Kwh)		23.86	20.40
ii)Through Steam Turbine		-	-
Generator Unit (Lakh kwh)		-	-
Unit per tonne of fuel (kwh)		-	-
Cost/unit (Rs/kwh)		-	-
2)Coal		-	-
3)Furnace Oil		-	-
4)Others/internal generation		-	-
B)TECHNOLOGY ABSORPTION			
I)Research & Development (R & D)		NIL	NIL
II) Technology absorption, adoption & Innovation		NIL	NIL
Foreign Exchange Earned	(Rs in lacs)	--	--
Foreign Exchange used	(Rs in lacs)	--	--

Performance Evaluation Policy

1. Introduction

The Advik Laboratories Limited (**"The Company"**) conducts its operations as per the directions provided by the Board of Directors within the framework laid down by the Companies Act, 2013 (**"the Act"**), the Articles of Association, Listing Agreement with stock exchanges and Code of Conduct and policies formulated by the Company for its internal execution. The Company's Board of Directors is dedicated to act in good faith; exercise their judgment on an informed basis, in the best interest of the company and its stakeholders.

The Act provides that the Nomination and Remuneration Committee shall formulate the criteria for evaluation of performance of Independent Directors and the Board. Such an evaluation procedure will provide a fine system of checks and balances on the performance of the directors and will ensure that they exercise their powers in a rational manner. The Act further casts an obligation on part of the board of directors for evaluating the performance of independent directors. All the directors on the board of a company, except the independent director whose performance is being evaluated, will assess the performance of the independent director. Accordingly, a report of performance evaluation of each independent director of the company would be prepared, which would determine whether to extend or continue the term of appointment of the concerned independent director or not.

As one of the most important functions of the Board of Directors is to oversee the functioning of Company's top management, this Board Performance Evaluation process aims to ensure individual directors (**"Directors"**) and the Board of Directors of the Company (**"Board"**) as a whole work efficiently and effectively in achieving their functions. This policy aims at establishing a procedure for conducting periodical evaluation of its own performance and individual directors. Hence, it is important that every individual Board Member effectively contributes in the Board deliberations.

2. Role of Board and Independent Directors

In conformity with the requirement of the Act, the performance evaluation of all the Independent Directors shall be done by the entire Board of Directors, excluding the director being evaluated.

The Independent Directors are duty bound to evaluate the performance of non – independent directors and Board as a whole. The independent directors of the Company shall meet at least once in a year to review the performance of the non- independent directors, performance of Chairperson of the Company and Board as a whole, taking into account the views of executive directors and non-executive directors.

3. Evaluation Criteria

The Board of Directors shall pay regards to the following parameters for the purpose of evaluating the performance of a particular director. In respect of each of the evaluation factors, various aspects have been provided to assist with the evaluation process in respect of performance of Board itself, and individual directors. Such evaluation factors may vary in accordance with their respective functions and duties. Evaluation of Independent Director shall be carried on by the entire Board in the same way as it is done for the Executive Directors of the Company except the Director being evaluated.

Appraisal of each Director of the Company shall be based on the criteria as mentioned herein below.

Rating Scale:

Performance	Rating
Excellent	4
Very Good	3
Good	2
Satisfactory	1
Not Satisfactory	0

Evaluation of Independent Directors

While evaluating the performance of Independent Directors following points needs to be considered.

Name of the Director being assessed: _____

Sr. No.	Assessment Criteria	Rating	Remarks/ Comments
1.	Attendance and participations in the meetings		
2.	Raising of concerns to the Board		
3.	Safeguard of confidential information		
4.	Rendering independent, unbiased opinion and resolution of issues at meetings.		
5.	Initiative in terms of new ideas and planning for the Company.		

6.	Safeguarding interest of whistle-blowers under vigil mechanism.		
7.	Timely inputs on the minutes of the meetings of the Board and Committee's, if any		
8.	Compliance with Article of Association, Companies Act, Listing Regulations & other laws applicable to the Company		
9.	Contribution to development of strategy and to risk management		
10.	Updatons with latest developments		
11.	Communications with Board members, senior management and others		

Evaluation of Non Independent/ Executive Directors

While evaluating the performance of Non-Independent Directors/ Executive Directors following point's needs to be considered:

Name of the Director being assessed: _____

Sr. No.	Assessment Criteria	Rating	Remarks/ Comments
1.	Leadership initiative		
2.	Initiative in terms of new ideas and planning for the Company		
3.	Professional skills, problem solving and decision making		
4.	Compliance with policies of the Company, ethics, Code of Conduct etc.		
5.	Reporting of frauds, violations etc.		
6.	Motivating employees, providing assistance & directions		
7.	Attendance and presence in meeting of Board, Committee and General Meeting.		
8.	Safeguarding of interest of whistle blowers under vigil mechanism.		
9.	Timely inputs of the minutes of the meetings of the Board and Committee, if any.		
10.	Compliance with Article of Association, Companies Act, Listing Regulations & other laws applicable to the Company		
11.	Contribution to development of strategy and to risk management		
12.	Updatons with latest developments		
13.	Communications with Board members, senior management and others		

Evaluation of Board of Directors

While evaluating the Performance of the Board of Directors as a whole, following points needs to be considered:

Sr. No.	Assessment Criteria	Rating	Remarks/ Comments
1.	The Board of Directors of the company is effective in decision making		
2.	The Board of Directors is effective in developing a corporate governance structure that allows and encourages the Board to fulfill its responsibilities.		
3.	The Company's systems of control are effective for identifying material risks and reporting material violations of policies and law.		
4.	The Board reviews the organization's performance in carrying out the stated mission on a regular basis.		
5.	The Board of Directors is effective in providing necessary advice and suggestions to the company's management.		
6.	Is the board as a whole up to date with latest developments in the regulatory environment and the market?		
7.	The information provided to directors prior to Board meetings meets your expectations in terms of length and level of detail.		
8.	Board meetings are conducted in a manner that encourages open communication, meaningful participation, and timely resolution of issues.		
9.	The Board Chairman effectively and appropriately leads and facilitates the Board meetings and the policy and governance work of the board.		
10.	The Board appropriately considers internal audit reports, management's responses, and steps towards improvement.		
11.	The Board oversees the role of the independent auditor from selection to termination and has an effective process to evaluate the independent auditor's qualifications and performance.		
12.	The Board considers the independent audit plan and provides recommendations.		

COMMITTEES OF BOARD

The Board has constituted the following committees:

1. Audit Committee;
2. Stakeholders Relationship Committee;
3. Nomination and Remuneration Committee;
4. Risk Management Committee

For evaluating the performance of each committee, the Board of Directors shall pay regards to the following aspects:

Sr. No.	Assessment Criteria	Rating	Remarks/ Comments
1.	Compliance with Article of Association, Companies Act, Listing Regulations & other laws applicable to the Company		
2.	Compliance with ethical standards & code of conduct of Company		
3.	Committee's accomplishments w.r.t. performance objectives		
4.	Redressal of complaints & grievances		
5.	Coordination with other committees and Board of Directors		
6.	Fulfillment of roles & responsibilities assigned to them		
7.	Adherence to Company's policies and internal procedures		

Evaluation of Key Management Personnel and Senior Executives

While evaluating the performance of Key Management Personnel and Senior Executives (other than Directors) following points shall be kept in mind:

Sr. No.	Assessment Criteria	Rating	Remarks/ Comments
1.	Abidance and behavior in accordance with ethical standards & code of conduct of Company.		
2.	Compliance with Article of Association, Companies Act, Listing Regulations & other laws. Applicable to the Company		
3.	Interpersonal and communication skills		
4.	Team work attributes		
5.	Safeguard of confidential information		
6.	Compliance with policies of the Company, ethics, code of conduct, etc.		
7.	Punctuality and other personality related aspects		

5. Review of the Policy

The Committee may amend the Policy, if required, to ascertain its appropriateness as per the needs of the Company.

6. Disclosure

Company will disclose details of its Board Performance Evaluation processes in its Board's report. The Board's report containing such statement shall indicate the manner in which formal evaluation has been made by the Board of its own performance and individual directors of the Company.

For and on Behalf of the Board of Directors of Advik Laboratories Ltd.

Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423

Date: 01st September, 2018
Place: New Delhi

NOMINATION & REMUNERATION POLICY

(As amended w.e.f. 10th November, 2015)

1. Introduction

Pursuant to Section 178 of the Companies Act, 2013 and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of had constituted the Nomination and Remuneration Committee. The Company considers human resources as its invaluable assets. This policy on nomination and remuneration of Directors, Key Managerial Personnel (KMPs) and other employees has been formulated in terms of the provisions of the Companies Act, 2013 read along with the applicable rules thereto and Listing Regulations, 2015, as amended from time to time. This policy on nomination and remuneration of Directors, Key Managerial Personnel and Senior Management has been formulated by the Nomination and Remuneration Committee (NRC or the Committee) and has been approved by the Board of Directors.

2. Objective and purpose of the policy

The objectives and purpose of this policy are:

1. To formulate the criteria for determining qualifications, competencies, positive attributes and independence for appointment of a Director (Executive / Non-Executive) and recommend to the Board policies relating to the remuneration of the Directors, Key Managerial Personnel and other employees. This includes, reviewing and approving corporate goals and objectives relevant to the compensation of the Chief Executive Officer (“CEO”), evaluating the CEO's performance in light of those goals and objectives, and either as a committee or together with the other independent directors (as directed by the board), determine and approve the CEO's compensation level based on this evaluation; and making recommendations to the board with respect to non-CEO executive officer compensation, and incentive-compensation and equity-based plans that are subject to board approval;
2. The policy also addresses the following items: Committee member qualifications; Committee member appointment and removal; Committee structure and operations; and Committee reporting to the Board.
3. To formulate the criteria for evaluation of performance of all the Directors on the Board;
4. To devise a policy on Board diversity; and
5. To lay out remuneration principles for employees linked to their effort, performance and achievement relating to the Company's goals.

Definitions

- ‘Board’ means Board of Directors of the Company.
- ‘Directors’ means Directors of the Company.
- ‘Committee’ means Nomination and Remuneration Committee of the Company as constituted or reconstituted by the Board, in accordance with the Act and applicable SEBI listing Regulations, 2015 and/or any other Act/Regulations.
- ‘Company’ means Advik Laboratories Limited.
- Independent Director’ means a Director referred to in Section 149(6) of the Companies Act, 2013 and rules.
- ‘Key Managerial Personnel (KMP)’ means-
 - (i) the Managing Director or the Chief Executive Officer or the manager and in their absence, a Whole-time Director;
 - (ii) the Company Secretary; and
 - (iii) the Chief Financial Officer

Senior Management means personnel of the company who are members of its core management team excluding Board of Directors comprising all members of management one level below the Executive Directors, including the functional heads.

Unless the context otherwise requires, words and expressions used in this policy and not defined herein but defined in the Companies Act, 2013 and Listing as may be amended from time to time shall have the meaning respectively assigned to them therein.

General

This Policy is divided in three parts: -

Part – A covers the matters to be dealt with and recommended by the Committee to the Board;

Part – B covers the appointment and nomination; and

Part – C covers remuneration and perquisites etc.

Part – A

Matters to be dealt with, perused and recommended to the Board by the Nomination and Remuneration Committee

The following matters shall be dealt by the Committee:-

(a) Size and composition of the Board:

Periodically reviewing the size and composition of the Board to ensure that it is structured to make appropriate decisions, with a variety of perspectives and skills, in the best interests of the Company as a whole and ensure compliance of various provision of applicable laws and SEBI listing Regulations, 2015;

(b) Directors:

Formulate the criteria determining qualifications, positive attributes and independence of a Director and recommending candidates to the Board, when circumstances warrant the appointment of a new Director, having regard to the range of skills, experience and expertise, on the Board and who will best complement the Board;

(c) Succession plans:

Establishing and reviewing Board and senior executive succession plans in order to ensure and maintain an appropriate balance of skills, experience and expertise on the Board and Senior Management;

(d) Evaluation of performance:

Make recommendations to the Board on appropriate performance criteria for the Directors.

Formulate the criteria and framework for evaluation of performance of every Director on the Board of the Company.

Identify ongoing training and education programs for the Board to ensure that Non-Executive Directors are provided with adequate information regarding the options of the business, the industry and their legal responsibilities and duties.

(e) Remuneration framework and policies:

The Committee is responsible for reviewing and making recommendations to the Board on:

- (i) the remuneration of the Managing Director, Whole-time Directors and KMPs
- (ii) the total level of remuneration of Non-Executive Directors and for individual remuneration for Non-Executive Directors and the Chairman, including any additional fees payable for membership of Board committees;
- (iii) the remuneration policies for all employees including KMPs, senior management and other employees including base pay, incentive payments, equity awards, retirement rights and service contracts having regard to the need to
- (iv) attract and motivate talent to pursue the Company's long term growth;
- (v) demonstrate a clear relationship between executive compensation and performance; and
- (vi) be reasonable and fair, having regard to best governance practices and legal requirements.
- (vii) The Company's superannuation arrangements and compliance with relevant laws and regulations in relation to superannuation arrangements; and
- (viii) the Company's remuneration reporting in the financial statements.

PART – B

Policy for appointment and removal of Director, KMPs and Senior Management

I. Appointment criteria and qualifications

1. The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director, KMP or senior management level and recommend to the Board his / her appointment.
2. A person to be appointed as Director, KMP or senior management level should possess adequate qualification, expertise and experience for the position he / she is considered for appointment. The Committee has discretion to decide whether qualification, expertise and experience possessed by a person is sufficient / satisfactory for the concerned position.
3. A person, to be appointed as Director, should possess impeccable reputation for integrity, deep expertise and insights in sectors / areas relevant to the Company, ability to contribute to the Company's growth, complementary skills in relation to the other Board members.

4. The Company shall not appoint or continue the employment of any person as Managing Director / Executive Director who has attained the age of seventy years and shall not appoint Independent Director who is below age of 21 years. Provided that the term of the person holding this position may be extended at the discretion of the committee beyond the age of seventy years with the approval of shareholders by passing a special resolution based on the explanatory statement annexed to the notice for such motion indicating the justification for extension of appointment beyond Seventy years as the case may be.
5. A whole-time KMP of the Company shall not hold office in more than one company except in its subsidiary company at the same time. However, a whole-time KMP can be appointed as a Director in any company, with the permission of the Board of Directors of the Company.

II. Term / Tenure

1. Managing Director / Whole-time Director

The Company shall appoint or re-appoint any person as its Managing Director and CEO or Whole-time Director for a term not exceeding five years at a time. No re-appointment shall be made earlier than one year before the expiry of term.

2. Independent Director

An Independent Director shall hold office for a term up to five consecutive years on the Board of the Company and will be eligible for re-appointment on passing of a special resolution by the Company and disclosure of such appointment in the Board's report.

No Independent Director shall hold office for more than two consecutive terms, but such Independent Director shall be eligible for appointment after expiry of three years of ceasing to become an Independent Director. Provided that an Independent Director shall not, during the said period of three years, be appointed in or be associated with the Company in any other capacity, either directly or indirectly.

At the time of appointment of Independent Director, it should be ensured that number of Boards on which such Independent Director serves is restricted to seven listed companies as an Independent Director and three listed companies as an Independent Director in case such person is serving as a Whole-time (Executive) Director of a listed company.

III. Retirement

The Whole-time Directors, KMP and senior management personnel shall retire as per the applicable provisions of the Companies Act, 2013 and the prevailing policy of the Company. The Board will have the discretion to retain the Whole-time Directors, KMP and senior management personnel in the same position / remuneration or otherwise, even after attaining the retirement age, for the benefit of the Company with the approval of shareholders by passing a special resolution at the general meeting of the Company.

PART – C

Policy relating to the remuneration for Directors, KMPs and other employees

A. General

1. The remuneration / compensation / commission etc. to Directors will be determined by the Committee and recommended to the Board for approval.
2. The remuneration and commission to be paid to the Managing Director shall be in accordance with the provisions of Chapter xiii of the Companies Act, 2013 read with schedule v, and the rules made thereunder.
3. Increments to the existing remuneration / compensation structure may be recommended by the Committee to the Board which should be within the limits approved by the Shareholders in the case of Managing Director.
4. Where any insurance is taken by the Company on behalf of its Managing Director, Chief Financial Officer, the Company Secretary and any other employees for indemnifying them against any liability, the premium paid on such insurance shall not be treated as part of the remuneration payable to any such personnel. Provided that if such person is proved to be guilty, the premium paid on such insurance shall be treated as part of the remuneration.

B. Remuneration to KMPs and other employees

The policy on remuneration for KMPs and other employees is as below:-

1. Fixed pay

The remuneration and reward structure for employees comprises two broad components - annual remuneration and long-term rewards. The Committee would determine the remuneration of the Directors and formulate guidelines for remuneration payable to the employees.

These guidelines are as under:

a) Annual remuneration

Annual remuneration refers to the annual compensation payable to the employees of the Company. This comprises two parts - a fixed component, and a performance-linked variable component based on the extent of achievement of the individual's objectives and performance of the business unit. Employee is required to determine his/her key result areas for that particular defined role. The performance-linked variable pay will be directly linked to the performance on individual components of the performance and the overall performance of the business. An employee's variable pay would, therefore, be directly dependent on key performance measures that represent the best interests of shareholders.

The objective is to set the total remuneration at levels to attract, motivate, and retain high-caliber, and high potential personnel in a competitive global market. The total remuneration level is to be reset annually based on a comparison with the relevant peer group globally, established through independent compensation surveys, from time to time.

b) Long-term rewards

Long-term rewards may be granted to eligible key employees based on their contribution to the performance of the Company, relative position in the organization, and length of service under the supervision and approval of the Committee.

The grant, vesting and other scheme details would be formulated from time to time.

These long-term reward schemes are implemented to attract and retain key talent in the industry.

2. Minimum remuneration to Managing Director/ Chief Executive officer

If, in any financial year, the Company has no profits or its profits are inadequate, the Company shall pay remuneration to its Managing Director in accordance with the provisions of Schedule V of the Companies Act, 2013 and if it is not able to comply with such provisions, with the previous approval of the Central Government.

C. Remuneration/ Setting Fees / Commission to Non-Executive / Independent Directors

1. Remuneration/ Setting Fees / Commission

The remuneration payable to each Non-Executive Director is based on the remuneration structure as determined by the Board, and is revised from time to time, depending on individual contribution, the Company's performance, and the provisions of the Companies Act, 2013 and the rules made there under.

The remuneration to the Non-executive Directors (including Independent Directors) may be paid within the monetary limit approved by shareholders, subject to the limit not exceeding 1% of the profits of the Company computed as per the applicable provisions of the Companies Act, 2013.

Non-Executive Directors/ Independent Director shall be paid a Setting Fees / Commission as may be decided by the Board of Directors from time to time subject to the limits specified in Companies Act, 2013 and other applicable laws/ Regulations.

2. Stock options

The Independent Directors shall not be entitled to any stock option of the Company.

Policy review

This policy is framed based on the provisions of the Companies Act, 2013 and rules there under and the requirements of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the Stock Exchanges.

In case of any subsequent changes in the provisions of the Companies Act, 2013 or any other regulations which makes any of the provisions in the policy inconsistent with the Act or regulations, then the provisions of the Act or regulations would prevail over the policy and the provisions in the policy would be modified in due course to make it consistent with law.

This policy shall be reviewed by the Nomination and Remuneration Committee as and when any changes are to be incorporated in the policy due to change in regulations or as may be felt appropriate by the Committee. Any changes or modification on the policy as recommended by the Committee would be given for approval of the Board of Directors.

**For and on Behalf of the Board of Directors of Advik
Laboratories Ltd.**

**Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423**

**Date: 01st September, 2018
Place: New Delhi**

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis

(a) Name(s) of the related party and nature of relationship	Not Applicable
(b) Nature of contracts/arrangements/transactions	
(c) Duration of the contracts / arrangements/transactions	
(d) Salient terms of the contracts or arrangements or transactions including the value, if any	
(e) Justification for entering into such contracts or arrangements or transactions	
(f) date(s) of approval by the Board	
(g) Amount paid as advances, if any:	
(h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188	

2. Details of material contracts or arrangement or transactions at arm's length basis:

(a) Name(s) of the related party and nature of relationship	Omkam Global Capital Private Limited
(b) Nature of contracts/arrangements/transactions	Unsecured Loan
(c) Duration of the contracts / arrangements/transactions	01/04/2017 to 31/03/2018
(d) Salient terms of the contracts or arrangements or transactions including the value, if any:	Mr. Peeyush Kumar Aggarwal, Director & Promoter of the Company is also a director & promoter of Omkam Global Capital Private Limited (OGCPL). For the smooth functioning of the company as well as for day to day funds requirements, the company had been requesting (OGCPL) and OGCPL has been infusing the funds. The funds received by the company are repayable on demand and/or as and when the company has surplus fund. During the year under review a sum of Rs. 30.37,000/- had been infused by the OGCPL, which has been fully adjusted/repaid at the end of the Financial year 2017-18 and nothing is pending/outstanding as on date.
(e) Justification for entering into such contracts or arrangements or transactions	Short Term fund required for day to day transactions
(f) date(s) of approval by the Board	30-05-2017
(g) Amount paid as advances, if any:	Nil
(h) Date on which the ordinary resolution was passed in general meeting as required under first proviso to section 188	29-09-2017

For and on Behalf of the Board of Directors of Advik Laboratories Ltd.

Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423

Date: 30th May, 2018
Place: New Delhi

Form No. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2018

[Pursuant to section 204(1) of the Companies Act, 2013 and rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To
The Members
M/s Advik Laboratories Limited
138, Roz- Ka- Meo Industrial Area,
Sohna Gurgaon,
Haryana-122103

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **M/s Advik Laboratories Limited** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

We report that:

- a) Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
- b) We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion. We have not verified the correctness and appropriateness of the financial records and Books of the Company.
- c) Where ever required, we have obtained the Management representation about the compliances of laws, rules and regulations and happening of events etc. The compliance of the provisions of the Corporate and other applicable laws, rules, regulations, standards is the responsibility of management.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March, 2018 ('Audit Period') complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2018 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'): —
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
 - (d) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014

notified on 28 October 2014;

- (e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
 - (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; and
 - (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998.
- (vi) Indian Stamp Act, 1899;
 - (vii) Indian Contract Act, 1872;
 - (viii) Income Tax Act, 1961 and indirect tax laws;
 - (ix) Central Excise and Service Tax Act;
 - (x) Central and State Sale Tax/Value Added Tax Laws;
 - (xi) Applicable Labour Laws; and
 - (xii) Other applicable Laws;

Having regard to the compliance system prevailing in the Company and on the basis of presentation and Reports made by Compliance Auditors and Internal Auditors of the Company, we further report that the Company has adequate system to ensure the compliance of the other applicable laws specifically to the Company.

We have also examined compliance with the applicable clauses of the following:

- Secretarial Standards issued by The Institute of Company Secretaries of India.
- Listing Agreements with Stock Exchanges in India.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc.

We further report that

- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the key managerial personnel that took place during the period under review were carried out in compliance with the provisions of the Act.
- Adequate system is required to exist for seeking and obtaining further information and clarifications on the agenda items before the meeting, circulation of notices before the prescribed time limit for the various meetings and for meaningful participation at the meeting and also for the proper and complied conduct of all the meetings in the company. All decisions at Board Meetings and Committee Meetings are carried out by majority as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be and further improvement will be appreciated.
- All decisions at Board Meetings and Committee Meetings are carried out by majority as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

We further report that based on the information received and records maintained there are adequate systems and processes in the Company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

For Kundan Agrawal & Associates
Company Secretaries
FRN: S2009DE113700

Place: Delhi
Date: 30.05.2018

Kundan Agrawal
Company Secretary
Membership No. 7631
C.P. No. 8325

Annexure – 7

DETAILS PERTAINING TO REMUNERATION AS REQUIRED UNDER SECTION 197(12) OF THE COMPANIES ACT, 2013 READ WITH RULE 5(1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

i. The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2017-18, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2017-18 and the comparison of remuneration of each Key Managerial Personnel (KMP) against the performance of the Company are as under:

S. No.	Name of Director/KMP and Designation	Remuneration of Director/KMP for Financial Year 2017-18 (Rs. In Lacs)	% Increase in Remuneration in the Financial Year 2017-18	Ratio of remuneration of each Director/ to median remuneration of employees	Comparison of the Remuneration of the KMP against the performance of the Company
1.	Mr. Sachin Garg Managing Director	NIL	Not Applicable	Not Applicable	Loss for the financial year 2017-18 is Rs. 105.69 Lacs as compare to loss of Rs. 744.42 Lacs for the financial year 2016-17.
2.	Mr. Peeyush Kumar Aggarwal Non Executive Director	NIL	Not Applicable	Not Applicable	
3.	Mr. Manoj Kumar Jain Independent Director	Not Applicable	Not Applicable	Not Applicable	
4.	Ms. Madhu Sharma Independent Director	Not Applicable	Not Applicable	Not Applicable	
5.	Mr. Manoj Bhatia Chief Financial Officer	4.62 Lacs	NIL	Not Applicable	Loss for the financial year 2017-18 is Rs. 105.69 Lacs as compare to loss of Rs. 744.42 Lacs for the financial year 2016-17.
6.	Ms. Pooja Chuni Company secretary	2.60 Lacs	NIL	Not Applicable	Loss for the financial year 2017-18 is Rs. 105.69 Lacs as compare to loss of Rs. 744.42 Lacs for the financial year 2016-17.

No sitting fee was paid to any of the Directors for attending Board Meeting/Committee Meetings.

- ii. In the financial year, there was an increase of 9% in the median remuneration of employees except Key Managerial Personnel. However, there was no increase in the remuneration of any KMPs of the company during the year under review;
- iii. There were 19 permanent employees on rolls of Company as on March 31, 2018;

- iv. Relationship between average increase in remuneration and company performance – The Company incurred a net loss for the year 2017-18 of 105.69 lacs, whereas the increase in median remuneration was 9%. The average increase in median remuneration was in line with the performance of the Company.
- v.
- a) Variations in the market capitalization of the Company: The market capitalization as on March 31, 2018 was Rs. 802.68 lacs as compared to market capitalization of Rs. 1528.91 lacs on March 31, 2017.
- b) Price Earnings ratio of Company was Rs. (9.33) as at March 31, 2018 and was Rs. (2.07) as at March 31, 2017.
- c) The closing price of the Company's equity shares on the BSE as on March 31, 2018 was Rs. 4.20/- per share.
- vi. The Key Parameters for any variable component of remuneration availed by the Directors – Please refer to the salient features of Remuneration Policy annexed and forming part of this Report.
- vii. Average percentage in increase made in the salaries of employees other than the managerial personnel in the last financial year i.e. 2017-18 was 9%
- viii. The ratio of the remuneration of the highest paid director to that of the employees who are not directors but receive remuneration in excess of the highest paid director during the year – Not Applicable; and
- ix. It is hereby affirmed that the remuneration paid to KMP and other employees is as per the as per the Remuneration Policy for Directors, Key Managerial Personnel and other Employees.
- x. None of the employees of the Company are related to any Director of the Company.

**For and on Behalf of the Board of Directors of Advik
Laboratories Ltd.**

**Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423**

**Date: 01st September, 2018
Place: New Delhi**

Report on Corporate Governance

Philosophy on Code of Corporate Governance

Your Company stand committed to good Corporate Governance - transparency, accountability, disclosure and independent supervision to increase the value to the stakeholders. The Company is committed to transparency in all its dealings with shareholders, employees, the Government and other parties and places high emphasis on business ethics. The basic philosophy of Corporate Governance in the Company is to achieve business excellence and increasing long-term shareholder value, keeping in view the interests of the company’s stakeholders. Your company believes that Corporate Governance is a powerful tool for building trust and long-term relationship with stakeholders, employees, customers and suppliers. The Company has consistently endeavored to be transparent in all areas of its operations.

Corporate Governance to the Company is not just a compliance issue but central guiding principle for everything it does. It’s a way of thinking, way of conducting business and a way to steer the organization to take on challenges for now and for the future. The following report on the implementation of the Corporate Governance code is a sincere effort of the Company to follow the Corporate Governance Principles in its letter and spirit.

Your Directors are committed to good Governance practices and the company has been sharing all important information about its various business segments and operations of the company through Directors Report, Quarterly Results, Chairman’s Statement and Annual Reports. Further as required by the listing agreement, report on Corporate Governance is given below:

Board of Directors

The Company is managed by well- qualified professionals. All directors are suitably qualified, experienced and competent .The members of the Board of Directors are persons with considerable experience and expertise in Audit, Accounts, Finance, Administration and Marketing. The Company is benefited by the experience and skills of the Board of Directors.

The Board of Directors consists of four members, comprising of one Managing Director, one Non Executive Promoter Director and two Non-Executive Independent Directors including one Woman Director. The Board’s composition meets the stipulated requirements of Regulation 17 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

None of the Directors hold directorship in more than ten public limited companies or act as an Independent Director in more than seven Listed Companies, none of the Directors acts as a member of more than ten or Chairman of more than five Committees as on 31st March, 2018 across all public limited companies in which they are Directors.

Board Meetings

The Board of Directors formulates the business policies of the company, reviews the performance and decides on the main issues concerning the company. During the year under review, Eight Board Meetings were held on 30th May, 2017, 20th June, 2017, 02nd September, 2017, 14th September, 2017, 14th December, 2017, 01st February, 2018 & 14th February, 2018, 01st March, 2018.

Details of attendance of each Director at various meetings of the Company are as follows:

Name	Category and Designation	No. of Board Meeting		Whether attended last AGM Yes/No	No. of Committees of Chairmanship/ Membership of Board Committees* (including this listed entity)		Number of Director ships Held in public companies	No. of Shares and convertible instruments held by Executive/ Non-Executive Directors
		Held	Attended		Chairman	Members		
Mr. Peeyush Kumar Aggarwal	Non-Executive, Promoter Director	8	8	Yes	1	2	5	19,57,159
Mr. Sachin Garg	Executive Director	8	8	Yes	0	2	3	NIL
Mr. Manoj Kumar Jain	Non-Executive Independent Director	8	8	Yes	5	1	3	NIL
Ms. Madhu Sharma	Non-Executive, Independent Director	8	8	Yes	2	3	5	NIL

* As per the requirements of Regulations 26 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Chairmanship and Membership of the Audit Committee and Stakeholders' Relationship Committees in other Public Limited Companies is mentioned only.

The Board of Directors has complete access to any information within the Company. At the Board Meetings, Directors are provided with all the relevant information on important matters, working of the Company as well as related details that require deliberations by the members of the Board.

Relationship between Directors

None of the Directors are related to each other.

Induction and Familiarization Programme for Independent Directors

On appointment, the concerned Directors is issued a letter of Appointment setting out in detail, the terms of appointment, duties and responsibilities. Each newly appointed Independent Director is taken through a familiarization programme. The programme aims to familiarize the Directors with their role, rights and responsibilities, nature of business model of the Company, etc.

The Details of the familiarization programme held for the Independent Directors are available on the Company's website i.e. http://www.advikindia.com/reports/policy/fpi_directors.pdf.

Independent Directors' Meeting

In compliance with Section 149(8) of the Companies Act, 2013, read alongwith Schedule IV of the Companies Act, 2013 and Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, one separate meeting of Independent Directors of the Company was held on 01.03.2018. The meeting was conducted in an informal manner without the presence of Managing Director, the Non Executive Mon Independent Director or any other Management Personnel.

All the Independent Directors were present at the meeting.

Performance Evaluation

In compliance with the provisions of the Companies Act, 2013 and as per the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has adopted a formal mechanism for evaluation of its performances as well as that of its committees and Individual Directors, including the Chairman of the Board. A structured questionnaire was prepared after taking into consideration inputs received from the Directors, covering various aspects of the Board's functioning such as adequacy of the composition of the Board and its Committees, Board culture, execution and performance of specific duties, obligations and governance and other criteria as set out in Performance Evaluation Policy.

A separate exercise was carried out to evaluate the performance of individual Directors including the Chairman of the Board. The performance evaluation of the Chairman and Non-Independent Directors was carried out by the Independent Directors. The Directors expressed their satisfaction with the evaluation process.

Board Committees

Your Company has various Committees which have been constituted by the Board of Directors as a part of good corporate governance practices and the same are in compliance with the requirements of the relevant provisions of applicable laws and Statutes. The details of various Committees constituted by the Board are as follows:

I. Audit Committee

The role and terms of reference of the Audit Committee are in accordance with Regulation 18 and Part C of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 177 of the Companies Act, 2013. This, inter alia, includes the overview of Company's financial reporting process, review of quarterly, half yearly and annual financial statements, review of internal control and internal audit systems, engage consultants who can analyze/review the internal practices and give a report thereon to the audit committee from time to time in respect of Company's Financial Reporting and controls thereto, recommendation for appointment, remuneration and terms of appointment of auditors of the company, review and monitor the auditors' independence, approval of any subsequent modification of transactions with the related parties, scrutiny of inter corporate loans and investments, etc.

During the year under review, Five Audit Committee Meetings were held on 30th May, 2017, 02nd September, 2017, 14th September, 2017, 14th December, 2017 and 14th February, 2018. The Committee is headed by a Non-Executive Independent Director. The Chairman of the Audit Committee was present at the last AGM held on 29.09.2017.

Details of attendance of each members of the Audit Committee are as under:

Name of the Director	Category	Number of meetings during the financial year 2017-18	
		Held	Attended
Mr. Manoj Kumar Jain	Chairman, Non-Executive, Independent Director	5	5
Mr. Sachin Garg	Executive Director, Member	5	5
Ms. Madhu Sharma	Non-Executive, Independent Director, Member	5	5

The Company Secretary of the Company also acts as the Secretary of the Audit Committee.

II. Nomination and Remuneration Committee

The constitution and terms of reference of the Committee are as per the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 and Part D of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The broad terms of reference of the Nomination and Remuneration Committee (NRC), inter alia, are as follows:

- Formulation of criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board of Directors a policy relating to the remuneration of directors, key managerial personnel and other employees..
- Formulation of criteria for evaluation of performance of Independent Directors and the Board of Directors.
- Devising a policy on diversity of board of directors.
- Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down and recommend to the Board of Directors their appointment and removal
- whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.

One meeting of the Nomination and Remuneration Committee was held on 01st March, 2018

The Composition of the Nomination and Remuneration Committee (NRC) as on March 31, 2018 and the attendance of each member at the Committee Meetings are as given below:

Name of Members	Status	Number of meetings during the financial year 2017-18	
		Held	Attended
Mr. Manoj Kumar Jain	Chairman	1	1
Mr. Peeyush Kumar Aggarwal	Member	1	1
Ms. Madhu Sharma	Member	1	1

Performance Evaluation

The Nomination and Remuneration Committee had laid down the criteria for performance evaluation of Independent Directors and other Directors, Board of Directors and Committees of the Board of Directors. The assessment was carried on the basis of following criteria:

- Valuable Input Provided;
- Dedication and Commitment;
- Industry Knowledge;
- Raising of Concern;
- Compliances under Companies Act;
- Contribution to development of strategy and to risk management.
- Updatations with the latest developments.
- Communication with other Board members, senior management and others

Remuneration of Directors

During the year under review, none of the Non-Executive Directors has entered into pecuniary relationship or transaction with the Company.

The detailed criteria for making remuneration to Non- executive Director is mentioned in the Nomination and Remuneration Policy of the Company and is displayed at the website of the Company at http://www.advikindia.com/reports/policy/nomination_remuneration.pdf. At present, none of the Non- Executive Directors is drawing any remuneration from the Company.

Mr. Peeyush Kumar Aggarwal, Non-Executive Promoter Director of the Company holds 1957159 equity shares of the Company as on 31st March, 2018. Apart from the Peeyush Kumar Aggarwal, none of the Directors hold any equity shares of the Company.

During the financial year 2017-18, no Stock Options were granted to any of the Directors. Further, none of the Directors is getting remuneration from the Company.

III. Stakeholders' Relationship Committee:

In Compliance with the provisions of Section 178 of the Companies Act, 2013 and Regulation 20 of the Listing Regulations, the Board has formed an "Stakeholders' Relationship Committee". Stakeholders' Relationship Committee reviews the redressal of grievances of stakeholders pertaining to the requests/complaints of the shareholders related to transfer/transmission of shares, Dematerialization/ Rematerialisation of shares, non-receipt of annual reports, non-receipt of dividend, recording the change of address and to deal with all related matters. The Minutes of the Committee are circulated to the Board of Directors.

The committee met 3 times during the year i.e on 02nd September, 2017, 16th October, 2017 and 06th January, 2018. The Composition of the Committee as on 31st March, 2018 and details of attendance of the Committee members at the meetings are given in the following table:

Name of Members	Status	Number of meetings during the financial year 2017-18	
		Held	Attended
Mr. Manoj Kumar Jain	Chairman	3	3
Mr. Sachin Garg	Member	3	3

Details of Investor complaints received and redressed during the Financial Year 2017-18 are as follows:

Opening Balance	Received during the year	Resolved during the year	Closing Balance
NIL	NIL	NIL	NIL

IV. Risk Management Committee

The Risk Management Committee's constitution and terms of reference are in compliance with provisions of the Companies Act, 2013 and Regulation 21 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company has a risk management programme which comprises of a series of processes, structures and guidelines to assist the Company to identify, assess, monitor and manage its business risks, including any material changes to its risk profile. The objectives and scope of the

Risk Management Committee broadly comprises:

- (i) Oversight of the risk management performed by the executive management,
- (ii) Review of the risk management policy,
- (iii) Reviewing risks and initiating mitigation activities,
- (iv) Defining framework for identification, assessment, monitoring, mitigation and reporting of risks.

During the Financial Year 2017-18, the Risk Management Committee met once on 01st March, 2018.

The Composition of the Risk management Committee as at March 31, 2018 and the attendance of each member at the Committee Meetings are as given below:

Name of Members	Status	Number of meetings during the financial year 2017-18	
		Held	Attended
Mr. Sachin Garg	Chairman	1	1
Mr. Peeyush Kumar Aggarwal	Member	1	1

Annual General Meetings

The details of last three Annual General Meetings are as follows:

Year	Date	Venue	Time
2015	29.09.2015	138, Roz Ka Meo Industrial Area, Sohna, Distt.Mewat, Haryana- 122103	10.00 A.M.
2016	30.09.2016	138, Roz Ka Meo Industrial Area, Sohna, Distt.Mewat, Haryana- 122103	11.30 A.M.
2017	29.09.2017	138, Roz Ka Meo Industrial Area, Sohna, Distt.Mewat, Haryana- 122103	10.15 A.M.

Special Resolutions passed during the last three Annual General Meetings:

The following special resolutions have been passed by the shareholders of the company in the previous three Annual General Meeting:

Sr. No.	Particulars of Special Resolutions passed	AGM Details
1.	Authorisation for the borrowing limits u/s 180(1)(c) of the Companies Act, 2013	21st AGM held on 29.09.2015
2.	Authorisation for Related Party Transaction u/s 188 of the Companies Act, 2013	22nd AGM held on 30.09.2016

Postal Ballot

During the year under review, no resolution was passed through Postal Ballot. None of the Businesses proposed to be transacted at the ensuing Annual General Meeting require passing of a special resolution through Postal Ballot.

Means of Communication

The quarterly audited/un-audited financial results are sent to all the Stock Exchanges where the Company's shares are listed i.e. BSE & ASE immediately after the conclusion of the Board Meetings.

The Company regularly publishes its Audited/Unaudited Financial Results, Notices of Board Meeting, E voting Notice and other Communications in the following Newspapers:

- For English Edition- Financial Express
- For Hindi Edition - Jansatta

The Company's website www.advikindia.com contains a separate section "Investor Information" where information for shareholders is available. The Company's website displays the information as stipulated under Regulation 46 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 such as Quarterly/Annual Financial Results, Annual Reports, Quarterly Corporate Governance Report, Shareholding Pattern, Policies, Investors' Contact details etc.

In addition, the Company makes use of this website for publishing official news release, if any.

General Shareholders' Information

Details of 24th Annual General Meeting of the Company

Day & Date	Friday 28 th September, 2018
Time	10:00 A.M.
Venue	138, Roz KaMeo Industrial Area, Sohna, Distt. Mewat, Haryana- 122103

Calendar for the financial year ending 31st March, 2019

Financial Reporting for the	Tentative time frame
First quarter ended 30th June, 2018	First fortnight of August, 2018
Second quarter ending 30th September, 2018	First fortnight of November, 2018
Third quarter ending 31st December, 2018	First fortnight of February, 2019
Fourth quarter ending 31st March, 2019	By the end of May, 2019

Date of Book Closure

From 22nd September, 2018 to 28th September, 2018 (both days Inclusive) for the purpose of Annual General Meeting.

Listing on Stock Exchanges

Name and Address of the Stock Exchanges	Stock Code
The Bombay Stock Exchange Ltd (BSE) 1st Floor, P.J. Towers, Dalal Street, Mumbai-400001	Scrip Code– 531686
Ahmedabad Stock Exchange Limited, 1st Floor, Kamdhenu Complex, Opp. Sahajanand College Panjara Pole Ahmedabad – 380015	Scrip Code– 01636

Listing Fees

The Listing Fees of the Bombay Stock Exchange (BSE) is pending. The Company is in the process of making the payment of the same.

CIN Number: L74899HR1994PLC038300

ISIN No.

The Company's Demat International Security Identification Number (ISIN) for its equity shares in NSDL and CDSL is INE 537C 01019.

Stock Market Data

The Company's equity shares are listed at Bombay Stock Exchange Ltd. (BSE) and Ahmedabad Stock Exchange Ltd. (ASE). Since there was no trading in the shares of the company at ASE, the share price market data is not available from ASE.

The monthly high and low quotations of equity shares traded on the Bombay Stock Exchange Limited during the financial year 2017-18 are as follows:

Share prices on Bombay Stock Exchange Limited (BSE Ltd.)* are as under:-

Company :ADVIK LABORATORIES LTD. 531686

Period: Apr 2017 to March, 2018

All Prices in ₹

Month	Open	High	Low	Close	No. of Shares	No. of Trades	Total Turnover	Deliverable Quantity	% Deli. Qty to Traded Qty	* Spread	
										H-L	C-O
Apr 17	8.39	8.43	5.92	6.66	1,03,320	313	7,15,404	1,03,320	100.00	2.51	-1.73
May 17	6.97	6.97	5.40	5.60	3,17,300	175	18,40,790	3,17,300	100.00	1.57	-1.37
Jun 17	5.32	6.25	4.58	5.35	1,65,585	137	8,80,168	1,65,585	100.00	1.67	0.03
Jul 17	5.22	6.05	5.00	5.50	45,025	157	2,36,871	45,025	100.00	1.05	0.28
Aug 17	5.72	5.77	4.45	4.68	44,321	118	2,17,919	44,321	100.00	1.32	-1.04
Sep 17	4.68	5.10	4.18	5.00	99,801	186	4,49,038	99,801	100.00	0.92	0.32
Oct 17	5.00	5.00	3.95	4.39	83,560	171	3,51,559	83,560	100.00	1.05	-0.61

Nov 17	4.50	6.59	3.99	5.23	1,29,279	302	7,06,969	1,29,279	100.00	2.60	0.73
Dec 17	5.23	5.86	4.21	5.43	1,11,174	309	5,63,135	1,11,174	100.00	1.65	0.20
Jan 18	5.66	7.37	5.17	6.00	1,60,945	489	9,99,216	1,60,945	100.00	2.20	0.34
Feb 18	6.30	6.30	4.65	4.90	30,978	91	1,70,710	30,978	100.00	1.65	-1.40
Mar 18	4.68	4.90	4.20	4.20	5,246	36	24,214	5,246	100.00	0.70	-0.48

Source: BSE's Website

The Equity Shares of the company have not been suspended from trading by SEBI and/or Exchanges, where the shares of the Company are listed.

Name and Address of the Registrar and Share Transfer Agent (RTA):

MAS Services Limited

T-34, IInd Floor
Okhla Industrial Area
Phase-II, New Delhi 110020
Tel :-011-26387281/82/83
Fax no.: +91-11-2638 7384
E-mail:info@masserv.com

Change in Registrar and Share Transfer Agent (RTA):

Please note that during the year under review, the Board of Directors of the company in its meeting held on 20/06/2017 has approved the change of Registrar and Share Transfer Agent (RTA) of the company from Beetal Financial & Computer Services (P) Ltd. to Mas Services Limited. Hence, at present the RTA of the Company is **MAS Services Limited**, the suitable intimation of which was duly sent to BSE and ASE from time to time.

Share Transfer System:

The Company's equity shares which are in dematerialized form are transferable through the dematerialized system. Equity Shares in physical form are processed by Registrar and Share Transfer Agent, M/s **MAS Services Limited** and approved by the Shareholders' Relationship Committee of the Board.

Reconciliation of Share Capital Audit Report:

A practicing Company Secretary carried out reconciliation of share capital audit to reconcile the total admitted capital with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) and the total issued and listed capital. The audit report confirms that the total issued/ paid up capital is in consonance with the total number of shares in physical form and the total number of dematerialized shares held with the depositories.

Distribution of Shareholding as on 31st March, 2018:

Nominal Value of Each Share : Rs. 10					
Share or Debenture holding Nominal Value (Rs.)	Number of Shareholders	% to Total Numbers	Share or Debenture holding	Share or Debenture holding Amount (Rs.)	% to Total Amount
1	2	3	4	5	6
Up To 5,000	3221	67.132	754398	7543980	3.947
5001 To 10,000	804	16.757	729837	7298370	3.819
10001 To 20,000	382	7.962	632054	6320540	3.307
20001 To 30,000	126	2.626	334453	3344530	1.750
30001 To 40,000	40	0.834	147769	1477690	0.773
40001 To 50,000	66	1.376	316097	3160970	1.654
50001 To 1,00,000	91	1.897	670669	6706690	3.509
1,00,000 and Above	68	1.417	15526123	155261230	81.240
Total	4798	100.00	19111400	191114000	100.00

Dematerialisation of Shares and Liquidity

The Company shares are traded in dematerialized form and have to be delivered in the dematerialized form to all Stock Exchanges. To enable shareholders an easy access to the de-mat system, the Company has executed agreements with both existing Depositories namely National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). M/s. MAS Services Ltd. is the Registrar and Transfer Agent of the Company for the purposes of electronic connectivity for effective dematerialization of shares. As of 31st March, 2018 shares comprising approximately 99.93% of the Company's Equity Share Capital have been dematerialized.

Status of Dematerialised Shares as on 31st March, 2018 (Equity ISIN No. INE 537C 01019)

Shares Held through	No. of Shares	Percentage of Holding
NSDL	13754939	71.97
CDSL	5343681	27.96
Physical	12780	0.07
Total	19111400	100.00

Shareholding Pattern of the Company as on 31st March, 2018

Category	No. of Shares held	% of share holding
A. Promoters' holding		
Promoters		
Indian Promoters		
• Individual	19,57,159	10.24
• Bodies Corporates	49,02,322	25.65
Foreign Promoters	Nil	Nil
2. Persons Acting in Concert	Nil	Nil
Sub-total (A)	6859481	35.89
B. Non-Promoters' holding		
3. Institutional Investors		
a. Mutual Funds & UTI	Nil	Nil
b. Banks, Financial Institutions, Insurance Companies (Central/State Government Institutions/Non-government Institutions)	Nil	Nil
c. FIIs	Nil	Nil
Sub-total	Nil	Nil
4. Non Institutional Investors		
a. Bodies Corporate	59,74,127	31.26
b. individuals		
-Individual shareholders holding nominal share capital up to Rs. 2 Lakhs	37,71,920	19.74
-Individual shareholders holding nominal share capital up in excess of Rs. 2 Lakhs	23,43,241	12.26
c. Any Other		
NRI	16,167	0.08
NBFCs	1,10,280	0.58
Clearing Members	36,184	0.19
Sub-total (B)	1,22,51,919	64.11
Grand Total (A)+(B)	1,91,11,400	100.00

ADRs/GDRs/Warrant:

The Company has not issued any ADRs/GDRs/Warrants or any other convertible instruments during the year under review.

Commodity Price Risk or Foreign Exchange Risk And Hedging Activities:

The Company is not involved into any activities relating to commodities price risks and hedging thereof.

Brief profile of the Directors liable to retire by rotation and others:

Brief resumes of the Director who is proposed to be re-appointed is furnished in the Directors' Report forming part of this Annual Report.

Address for Correspondence

Corporate Office:-

Advik Laboratories Limited
703, Arunachal Building,
19, Barakhamba Road,
Connaught Place,
New Delhi – 110001
Phones: 011 – 42424884
Fax: 011 – 43571047
Email id: mail@advikindia.com

Investor's Correspondence may be addressed to

The shareholders desiring to communicate with the Company on any matter relating to their shares of the Company may either visit in person or write quoting their Folio Number at the following address:

**The Company Secretary,
Advik Laboratories Limited
703, Arunachal Building,
19, Barakhamba Road,
Connaught Place,
New Delhi – 110001
Phone: 011 – 42424884
Fax: 011 – 43571047
Email id: mail@advikindia.com**

The Company is also maintaining a separate e-mail id. investor@advikindia.com for registering the investor Complaints and Grievances.

SEBI Complaints Redress System (SCORES):

SCORES, i.e., a SEBI Complaints Redress System is a centralized web based complaints redress system which serves as a centralised database of all Complaints received enables uploading of Action Taken Reports (ATR's) by the concerned Companies & online viewing by the investors of actions taken on the Complaint & its current status. Your Company is registered with SEBI under the SCORES system.

Prohibition of Insider Trading:

In compliance with SEBI's Regulations on Prevention of Insider Trading, the Company has formulated a Code of Conduct for prohibition and prevention of Insider Trading for all the Directors, Officers and the designated employees of the Company. The Code lays down the Guidelines and procedures to be followed and disclosures to be made while dealing with equity shares of the Company.

CEO/CFO Certification:

The Managing Director and Chief Financial Officer of the company has issued certificate pursuant to Regulation 17(8) read with Part B of Schedule II of the Listing Regulations certifying that the financial statements and the cash flow statement do not contain any untrue statements and these statements represent a true and fair view of the Company's affairs. The same is annexed to this Report.

Auditors' Certificate on Corporate Governance

A Certificate has been obtained from the Auditors of the Company regarding compliance with the provisions relating to Corporate Governance laid down in Schedule V (E) of the SEBI (LODR) Regulations, 2015. The same is annexed to this report.

Disclosures:

- (i) There were no transactions of the material nature with the related parties during the year that may have potential conflict with the interests of the Company at large. The policy on related party transaction is available in the website of the Company i.e. http://www.advikindia.com/index.php?option=com_content&view=article&id=56&Itemid=57.
- (ii) There was no instance of non-compliance and no penalties or strictures were imposed on the Company by any Stock Exchanges or SEBI or any other Statutory Authorities on any matter related to the Capital Markets during the last three years.
- (iii) The Company has formulated a Whistle Blower Policy to establish a Vigil Mechanism for directors and employees of the Company. The Whistle Blower Policy/Vigil Mechanism policy is available in the website of the Company i.e. http://www.advikindia.com/reports/policy/whistle_blower.pdf. Further, no employee has been denied access to the Audit Committee.
- (iv) The Company has complied with all the mandatory requirements of Corporate Governance of the Listing Regulations as are applicable to the company. The Company also endeavors to follow Non-Mandatory requirements.
- (v) The Company is not involved into activities relating to commodity price risks and hedging thereof

Details of Compliance with mandatory requirements and adoption of non-mandatory requirements of the Listing Regulations:

The Company has complied with all the Mandatory requirements as prescribed under the SEBI (LODR) Regulations, 2015 to the extent applicable, including Corporate Governance requirements as specified under Regulation 17 to 27 and Clause (b) to (i) of Sub-Regulation (2) of Regulation 46 of the Listing Regulations as applicable to the Company.

A Certificate from M/s. RMA and Associates LLP, the statutory auditors of the company confirming compliance with the conditions of corporate governance as specified under Schedule V (E) of the Listing Regulations is annexed to this Report. Further, the Company has also complied with all requirements about disclosures in the Corporate Governance Report, as specified in sub para (2) to (10) of Clause C of Schedule V of the Listing Regulations.

Non-Mandatory requirements of Regulation 27(1) and Part E of Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

1. The quarterly/half yearly results are not sent to the shareholders. However, the same are published in the newspapers and also posted on the Company's website.
2. The Internal Auditors report to the Audit Committee.

Disclosure of Accounting Treatment:

During the year under review, the Company has adopted Indian Accounting Standards ("Ind AS") notified by the Ministry of Corporate Affairs. The financial statements for the financial year 2017-18 have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting practices and policies to the extent applicable. The company has for the first time adopted Ind AS w.e.f. April 01, 2017 with a transition date of April 1, 2016.

As these are the first financial statements prepared in accordance with Indian Accounting Standards (Ind AS), Ind AS 101. First-time Adoption of Indian Accounting Standards has been applied.

Green Initiative in Corporate Governance:

The Ministry of Corporate Affairs (MCA) has taken a "Green Initiative in Corporate Governance" by allowing service of documents by a Company to its Members through electronic mode. The move of the Ministry allows public at large to contribute to the green movement.

Keeping in view the underlying theme, the Company will continue to send various communications and documents like notice calling general meetings, audited financial statements, directors' report, auditor's report etc., in electronic form, to the email address provided by the members to the Depositories or to the Company.

To support this green initiative in full measure, members/ Promoters who have not registered their E-mail address and PAN Number. so far, are requested to register their E-mail address and PAN Number and their Bank Account details, in respect of electronic holdings with the Depository through their concerned Depository Participant. Members who hold shares in physical

form are requested to fill their e-mail address and PAN Number and Bank Account Details for our records in the registration form which can be downloaded from the Company's website i.e. www.advikindia.com for sending the documents in electronic form or else sent a request letter directly to the Company mentioning their E-mail address and PAN No. and Bank Account Details alongwith self attested copy of their PAN Card. Necessary communication in this regard has already been sent separately to the shareholders by the Company.

Dematerialization of Shares

Shareholders are requested to convert their physical holding to demat/electronic form through any of the Depository Participants to avoid any possibility of loss, mutilation etc. of physical share certificates and also to ensure safe and speedy transaction in securities.

Further, SEBI vide Notification No. SEBI/LAD-NRO/GN/2018/24 dated 08-06-2018 has come out with SEBI (Listing Obligations and Disclosure Requirements) (fourth Amendment) Regulations, 2018 ("The New Regulations") to further amend the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The New Regulations shall come into force on the 180th day from the date of its publication in the official gazette i.e. 08.06.2018 (Effective Date of implementation is December 5, 2018). The New Regulations have inter alia amended the Regulation 40 of SEBI (LODR) Regulations, 2015 and as per amended Regulation 40, the requests for effecting transfer of securities shall not be processed unless the securities are held in the dematerialised form with a depository except in the cases of transmission or transposition of securities. In view of above amended Regulation, you are requested to open a de-mat account with a Depository Participant (DP) and deposit your physical shares with such DP and get your shares de-mat at the earliest, i.e., on or before 05.12.2018 to avoid any kind of inconvenience. Necessary communication in this regard has already been sent separately to the shareholders by the Company.

Consolidation of Multiple Folios:

Shareholders, who have multiple folios in identical names, are requested to apply for consolidation of such folios and the relevant share certificates to the Company/its Registrar and Transfer Agent.

Updation of Registered Address with the Company:

Shareholders are requested to update their addresses registered with the Company directly through the Share Transfer Agent, to receive all communications promptly. Shareholders holding shares in electronic form are requested to deal only with their Depository Participants in respect of change of address.

Code of Conduct

The Company has laid down a Code of Conduct for all Board Members and Senior Management Personnel. The Code of Conduct is also available on the website of the Company. All Board Members and Senior Management Personnel have affirmed compliance with the Code of Conduct for the year under review.

Declaration of Compliance of the Code of Conduct in terms of Schedule V of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

" In terms of Schedule V of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and as per affirmation received from the Directors and the Members of Senior Management Personnel of the Company, I hereby declare that Directors & the Members of Senior Management of the Company have complied with the Code Of Conduct during the F.Y. 2017-18.

For and on Behalf of the Board of Directors of
Advik Laboratories Ltd.

Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423

Date: 01st September, 2018
Place: New Delhi

AUDITOR' S CERTIFICATE ON COMPLIANCE WITH THE CONDITIONS OF CORPORATE GOVERNANCE

To,

**The Members of
Advik Laboratories Limited**

We have examined the compliance of conditions of Corporate Governance by Advik Laboratories Limited for the year ended 31st March, 2018 as per the provisions of SEBI (Listing Obligations & Disclosures Requirement) Regulations, 2015 (Listing Regulations) as referred to in Regulation 15(2) and Regulations 17 to 27 and other applicable Regulations and Schedules thereof of the Listing Regulations for the Financial Year 2017-18.

The Compliance of conditions of Corporate Governance is the responsibility of the management. Our examination was limited to procedures and implementation thereof, adopted by the company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the company has complied with the conditions of Corporate Governance as stipulated in the above mentioned SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as applicable.

We further state that such compliance is neither an assurance as to the further viability of the company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**For M/s. RMA & Associates LLP
Chartered Accountants
Firm Reg. No. 000978N/N500062
Sd/-
Amit Jain
Partner
Membership No. 503109**

**Place : New Delhi
Dated :30.05.2018**

CEO/CFO Certification

This is to certify to the Board that:

- a. We have reviewed the Financial Statements and the Cash Flow Statement for the year ended March 31, 2018 and that to the best of our knowledge and belief state that:
 - i. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - ii. these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- b. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or volatile of the Company's code of conduct.
- c. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- d. We have indicated to the Auditors and the Audit Committee:
 - i. significant changes in internal control over financial reporting during the year, whenever applicable;
 - ii. significant changes, if any, in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - iii. that there were no instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For Advik Laboratories Limited

**Sd/-
Sachin Garg
Managing Director
(DIN: 00175301)**

**Sd/-
Manoj Kumar Bhatia
Chief Financial Officer
(PAN: AAZPB5897R)**

**Place : New Delhi
Dated : 30.05.2018**

INDEPENDENT AUDITORS' REPORT

To the Members of
Advik Laboratories Limited,

Report on the IND AS Financial Statements

We have audited the accompanying IND AS Financial Statements of ADVIK LABORATORIES LIMITED ("The Company"), which comprise the Balance Sheet as at 31st March 2018, and the Statement of Profit and Loss (including other comprehensive income), the Statement of Cash Flows and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these IND AS Financial Statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (IND AS) prescribed under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2015.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these IND AS Financial Statements based on our audit.

We have taken into account the provisions of the Act, the Accounting and Auditing Standards and matters which are required to be included in the Audit Report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the IND AS Financial Statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the IND AS Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the IND AS Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the IND AS Financial Statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the IND AS Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the IND AS Financial Statements.

Basis for Qualified Opinion

1. The Company has not determined the fair value of Investments in unquoted equity shares of other Companies as per IND AS 113 Fair Value Measurement.
2. Trade Receivables & Trade Payables are subject to confirmation, reconciliation, adjustments and provisions, if any which may arise out of confirmation and reconciliation.

Opinion

In our opinion, except for the effects of the matters described in the Basis of Qualified Opinion paragraph, and to the best of our information and according to the explanations given to us, the aforesaid IND AS Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including the IND AS, of the state of the affairs (financial position) of the Company as at 31st March, 2018, and its profit (financial performance including other comprehensive income), its cash flows and the changes in equity for the year ended on that date.

Report on other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the order"), issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, and on the basis of such checks of the books and records of the Company as we considered appropriate and according to the information and explanations given to us, we give in the Annexure "A" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by section 143(3) of the Act, we report that:-
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss including other comprehensive income, the Statement of Cash Flows and Statement of Changes in Equity dealt with by this Report are in agreement with the Books of Account.
 - d) In our opinion, the aforesaid IND AS Financial Statements comply with the Indian Accounting Standards prescribed under Section 133 of the Act, read with relevant rules issued thereunder.
 - e) On the basis of written representations received from the directors as on 31 March, 2018, taken on record by the Board of Directors, none of the directors is disqualified as on 31 March, 2018, from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B"; and
 - g) With respect to the other matters to be included in the Auditors' Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - I. The Company has disclosed the impact of pending litigations on its financial position in its IND AS financial statements-Refer **Note no. 24** to the IND AS financial statements.
 - II. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - III. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company during the year ended 31st March, 2018.

For M/s. RMA & Associates LLP
Chartered Accountants
Firm Regn. No. 000978N/N500062

Sd/-
(Amit Jain)
Partner
Membership No. 503109

Place: New Delhi
Dated : 30th May, 2018

ANNEXURE “A” TO THE INDEPENDENT AUDITORS’

The Annexure referred to in our report of even date

1. (a) Accordingly to the information and explanations given to us, the company has maintained proper records showing full particulars including quantitative details and situation of the fixed assets.
- (b) Accordingly to the information and explanations given to us, the fixed assets of the company have been physically verified by the management at reasonable intervals and no material discrepancies were noticed on such verification as compared to books of accounts.
- (c) Accordingly to the information and explanations given to us and on the basis of examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
2. According to the information and explanation given to us, Physical verification of inventory has been conducted at reasonable intervals by the Management of the Company, and no material discrepancies were noticed on physical verification conducted by the management
3. Accordingly to the information and explanations given to us, the company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013 during the year. Therefore, the provision of clause (iii) of Para 3 of the Companies (Auditor’s Report) Order, 2016 is not applicable to the company.
4. In our opinion and according to the information and explanations given to us, the Company has not given any loans, guarantees and security to any Director or to any other person in whom Director is interested in compliance with the section 185 & 186 of the Act.
5. The company has not accepted any deposits. Therefore, the provision of clause (v) of Para 3 of the Companies (Auditor’s Report) Order, 2016 is not applicable to the company.
6. As per notification no. F.No.1/40/2013-CL-V dated 31.12.2014 maintenance of cost records has not been prescribed by the Central Government U/s. 148(1) of the Companies Act, 2013.
7. (a) According to the information and explanations given to us and on the basis of our examination of the books of account of Company, the company is generally regular in depositing undisputed statutory dues including provident fund, employees state insurance, income-tax, service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues, as applicable with the appropriate authorities.

According to the information and explanation given to us, no other undisputed amounts are payable on account of provident fund, employees state insurance, income-tax, service tax, duty of customs, duty of excise, value added tax, as at 31.03.2018 for a period of more than six months from the date they become payable.

(b) According to the information’s and explanations given to us there are no pending dues in respect of Sales Tax, Wealth Tax, Service Tax, Value Added Tax, Duty of Customs and Cess which has not been deposited on account of any dispute.

8. According to information & explanation given to us and based on the documents and records produced before us, the company is not regular in depositing of its dues with their banker **Indian Overseas bank**, due to that banker has considered the company account as NPA.

Sr. No.	Principal due Amount in INR	Nature of Credit Facility	Remarks
1.	374.99 Lacs	Term Loan	Both Term Loans & Cash Credit Accounts are become NPA since 01.07.2014. Due to that interest of Rs. 398.16 on Term Loan & CC limits as on 31.03.2018 has not been accounted for.
2.	289.52 Lacs	Cash Credit Limit	

9. According to the information & explanation given to us and the records of the Company examined by us the Company has not raised any money by way of initial public offer or further public offer (including debt instruments) or term loans during the year.
10. During the course of our examination of the books and records of the Company carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instances of material fraud by the Company or on the Company by its officers or employees, noticed or reported during the year under audit, nor have we been informed of any such case by the Management.
11. No Managerial Remuneration is paid by the company during the year hence provisions of Section 197 read with Schedule V to Companies Act, 2013 are not applicable.
12. In our opinion and according to the information and explanations given to us, the Company is not a Nidhi Company. Therefore, the provisions of clause (xii) of Para 3 of the Companies (Auditor's Report) Order, 2016 are not applicable to the Company.
13. Based upon the Audit procedures performed and according to the information & explanations given to us, All transactions with related parties are in compliance with Section 177 and 188 of the Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc. as required by the applicable accounting standards.
14. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
15. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with Directors or persons connected with him. Therefore, the provisions of clause (xv) of Para 3 of the Companies (Auditor's Report) Order, 2016 are not applicable to the Company.
16. According to the information and explanation given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.

**For M/s. RMA & Associates LLP
Chartered Accountants
Firm Regn. No. 000978N/N500062**

**Sd/-
(Amit Jain)
Partner
Membership No. 503109**

**Place: New Delhi
Dated : 30th May, 2018**

ANNEXURE "B" TO THE INDEPENDENT AUDITOR'S REPORT OF "ADVIK LABORATORIES LIMITED" FOR THE YEAR ENDED 31st MARCH 2018.

Report on the internal Financial Controls under Clause (i) of Sub-Section 143 of the Companies Act 2013.

Report on the Internal Financial Controls

We have audited the Internal Finance Controls over financial reporting of "ADVIK LABORATORIES LIMITED" (the Company) as of 31st March 2018 in conjunction with our audit of the Financial Statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls.

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the institute of Chartered Accountants of India (ICAI) These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its, the prevention and detection of frauds and errors, the accuracy and

completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013 to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal Financial Controls and, both issued by the institute of Chartered Accounts of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining and understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the financial statement, where due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purpose in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place: New Delhi
Dated : 30th May, 2018

For M/s. RMA & Associates LLP
Chartered Accountants
Firm Regn. No. 000978N/N500062

Sd/-
(Amit Jain)
Partner
Membership No. 503109

Balance Sheet as at March 31, 2018

(Amount in Rs.)

Particulars	Note No.	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
I ASSETS				
(1) Non-Current assets				
(a) Property, Plant and Equipment	3	6,47,06,164	7,05,87,665	7,63,51,118
(b) Capital work-in-progress	3	5,20,64,024	5,51,01,024	6,15,20,184
(c) Financial Assets				
(i) Non Current Investments	4	92,30,000	92,30,000	92,30,000
(ii) Other non-current assets	5	38,259	61,366	86,123
Total Non-Current Assets		12,60,38,447	13,49,80,055	14,71,87,425
(2) Current assets				
(a) Inventories	6	57,45,162	1,13,26,510	7,53,10,138
(b) Financial Assets				
(i) Investments		-	-	-
(ii) Trade receivables	7	3,85,67,764	4,14,32,774	4,27,18,847
(iii) Cash and cash equivalents	8	1,55,512	5,52,621	3,11,881
(iv) Current Loans	9	2,09,99,654	2,09,68,416	2,01,66,094
(d) Other current assets	10	31,861	46,016	40,044
Total Current Assets		6,54,99,953	7,43,26,337	13,85,47,004
Total Assets		19,15,38,400	20,93,06,392	28,57,34,429
II EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	11	19,11,14,000	19,11,14,000	19,11,14,000
(b) Other Equity	12	(8,35,13,318)	(7,50,19,121)	(12,84,943)
		10,76,00,682	11,60,94,879	18,98,29,057
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings	13	-	-	97,60,531
(b) Provisions	14	14,74,900	12,78,394	18,41,682
(c) Deferred tax liabilities (Net)	15	73,20,677	92,34,214	97,99,655
(d) Other non-current liabilities		-	-	-
Total Non-Current Liabilities		87,95,577	1,05,12,608	2,14,01,868
(2) Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	13	2,89,52,213	2,89,52,213	2,89,52,213
(ii) Trade payables		13,72,254	36,30,394	64,41,604
(b) Other current liabilities	16	4,48,17,674	5,01,16,298	3,91,09,687
(c) Provisions		-	-	-
Total Current Liabilities		7,51,42,141	8,26,98,905	7,45,03,504
Total Equity and Liabilities		19,15,38,400	20,93,06,392	28,57,34,429

III NOTES FORMING PART OF THE FINANCIAL STATEMENTS 1-37

For RMA & Associates LLP

For and on behalf of the Board of Directors of Advik Laboratories Ltd.

Chartered Accountants

Firm Regn. No. : 000978N/N500062

Sd/-

(Amit Jain)

Partner

Membership No. 503109

Sd/-

(Peeyush Kumar Aggarwal)

Chairman

DIN:00090423

Sd/-

(Sachin Garg)

Managing Director

DIN:03320351

Sd/-

(Manoj Bhatia)

CFO

Sd/-

(Pooja Chuni)

Company Secretary

Place: New Delhi

Date: 30th May, 2018

Statement of Profit and Loss Account for the year ended March 31, 2018

(Amount in Rs.)

Particulars	Note No.	As at 31.03.2018	As at 31.03.2017
INCOME			
I Revenue From Operations	17	4,09,38,162	2,84,32,385
II Other Income	18	5,89,304	2,74,347
III Total Income (I+II)		4,15,27,466	2,87,06,732
EXPENSES			
IV Cost of materials consumed	19	3,01,68,884	4,61,70,482
Purchases of Stock-in-Trade		-	-
Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	20	51,06,965	3,62,05,875
Employee benefits expense	21	65,14,189	79,48,047
Finance costs	22	16,689	8,794
Depreciation and amortization expense	3	58,81,501	59,03,095
Other expenses	23	44,08,018	69,12,153
Total expenses (IV)		5,20,96,246	10,31,48,446
V Profit/(loss) before exceptional items and tax (III-IV)		(1,05,68,780)	(7,44,41,714)
VI Exceptional Items		-	-
VII Profit/(loss) before tax (V-VI)		(1,05,68,780)	(7,44,41,714)
Tax expense:			
VIII (1) Current tax		-	-
(2) Deferred tax		(19,13,537)	(5,65,441)
IX Profit (Loss) after Tax		(86,55,243)	(7,38,76,273)
X Other Comprehensive Income			
Remeasurement of net defined benefit liability or asset:		1,61,046	1,42,095
XI Total Comprehensive Income for the period		(84,94,197)	(7,37,34,178)
XII Earnings per equity share			
(1) Basic		(0.44)	(3.86)
(2) Diluted		(0.44)	(3.86)

XIII NOTES FORMING PART OF THE FINANCIAL STATEMENTS 1-37

For RMA & Associates LLP

Chartered Accountants

Firm Regn. No. : 000978N/N500062

For and on behalf of the Board of Directors of Advik Laboratories Ltd.

Sd/-

(Amit Jain)

Partner

Membership No. 503109

Sd/-

(Peeyush Kumar Aggarwal)

Chairman

DIN:00090423

Sd/-

(Sachin Garg)

Managing Director

DIN:03320351

Sd/-

(Manoj Bhatia)

CFO

Sd/-

(Pooja Chuni)

Company Secretary

Place: New Delhi

 Date: 30th May, 2018

Cash Flow Statement for the year ended March 31, 2018

Particulars	As at 31.03.2018 (Rs.)	As at 31.03.2017 (Rs.)
A. Cash Flow from operating activities		
Net profit before tax and extraordinary items	(1,05,68,780)	(7,42,99,619)
Add: Adjustment for Depreciation	58,81,501	59,03,095
Provision for Gratuity	2,04,440	97,292
Provision for Leave Encashment	58,947	51,611
Interest & Other Costs	16,689	8,794
Operating profit before working capital changes	(44,07,203)	(6,82,38,827)
Adjustment for:		
Increase / (Decrease) in Trade Payables	(22,58,140)	(28,11,210)
Increase / (Decrease) in Current Liabilities	(52,98,624)	1,10,06,611
(Increase) / Decrease in Trade Receivables	28,65,010	12,86,073
(Increase) / Decrease in Loans & Advances	(31,238)	(7,16,199)
(Increase) / Decrease in Non Current Assets	23,107	(61,366)
(Increase) / Decrease in Other Current Assets	14,155	(5,972)
(Increase) / Decrease in Inventories	55,81,348	6,39,83,628
Increase/(Decrease) Non Current Liabilities (Provision)	94,165	(7,12,191)
Cash Generated From Operations	(34,17,420)	37,30,547
Net Cash from operating activities (A)	(34,17,420)	37,30,547
B. Cash flow from investing activities		
Purchase of Capital Assets	30,37,000	62,79,518
Interest Received	-	-
Net cash outflow from investing activities (B)	30,37,000	62,79,518
C. Cash Flow from financing activities		
Repayment of long term borrowings	-	(97,60,531)
Interest Paid	(16,689)	(8,794)
Net cash used in financial Activities ©	(16,689)	(97,69,325)
Net Increase/ (Decrease) in cash (A+B+C)	(3,97,109)	2,40,740
Cash & Cash Equivalents (Opening balance)	5,52,621	3,11,881
Cash & Cash Equivalents (Closing balance)	1,55,512	5,52,621

For RMA & Associates LLP
Chartered Accountants
Firm Regn. No. : 000978N/N500062

For and on behalf of the Board of Directors of Advik Laboratories Ltd.

Sd/-
(Amit Jain)
Partner
Membership No. 503109

Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN:00090423

Sd/-
(Sachin Garg)
Managing Director
DIN:03320351

Sd/-
(Manoj Bhatia)
CFO

Sd/-
(Pooja Chuni)
Company Secretary

Place: New Delhi
Date: 30th May, 2018

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR 31ST MARCH 2018

Particulars	Equity capital	Share	Reserve & surplus	Other comprehensive Income	Total	Total Equity & Other Equity
Balance as of April 1, 2016	19,11,14,000		(12,84,943)	--	(12,84,923)	18,98,29,057
Changes in the Equity for the year ended March 31, 2017						
Remeasurement of net defined benefits Liability				1,42,095	1,42,095	1,42,095
Loss for the period			(7,38,76,273)		(7,38,76,273)	(7,38,76,273)
Balance as of March 31, 2017	19,11,14,000		(7,51,61,216)	1,42,095	(7,50,19,121)	11,60,94,879

Particulars	Equity capital	Share	Reserve & surplus	Other comprehensive Income	Total	Total Equity & Other Equity
Balance as of April 1, 2017	19,11,14,000		(7,51,61,216)	1,42,095	(7,50,19,121)	11,60,94,879
Changes in the Equity for the year ended March 31, 2018						
Remeasurement of net defined benefits Liability				1,61,046	1,61,046	1,61,046
Loss for the period			(86,55,243)		(86,55,243)	(86,55,243)
Balance as of March 31, 2018	19,11,14,000		(8,38,16,459)	3,03,141	(8,35,13,318)	10,76,00,682

For RMA & Associates LLP
Chartered Accountants
Firm Regn. No. : 000978N/N500062

For and on behalf of the Board of Directors of Advik Laboratories Ltd.

Sd/-
(Amit Jain)
Partner
Membership No. 503109

Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN:00090423

Sd/-
(Sachin Garg)
Managing Director
DIN:03320351

Sd/-
(Manoj Bhatia)
CFO

Sd/-
(Pooja Chuni)
Company Secretary

Place: New Delhi
Date: 30th May, 2018

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018**1 COMPANY OVERVIEW & SIGNIFICANT ACCOUNTING POLICIES****I COMPANY OVERVIEW**

Advik Laboratories Limited is Public limited company, incorporated under the Indian Companies Act, 1913, having its registered office in Sohna, Haryana and is listing on BSE Ltd & ASE Ltd. The Company is engaged in manufacturing, marketing, trading and export of Pharmaceutical Products. The Company has its own manufacturing facility at Sohna. The Company has various independent contract/third party manufacturers based across the country.

II SIGNIFICANT ACCOUNTING POLICIES**a. BASIS OF PREPARATION OF FINANCIAL STATEMENTS**

The Company has adopted Indian Accounting Standards (IND AS) notified by the Ministry of Corporate Affairs under the Companies (Accounting Standards) Rules 2015 and Companies (Accounting Standards) Rules 2016 with effect from 1st April 2017. The adoption of the IND AS was carried out in accordance with the IND AS 101 First Time adoption of Indian Accounting Standards. Please refer to Note No. 2 for more information on reconciliations of differences and descriptions of the effect of transition. The transition of IND AS as resulted in changes in the presentation of the Financial Statements, disclosures in the notes thereto and accounting policies and principles. The accounting policies set out in Note 1 have been applied in preparing the standalone financial statements for the year ended March 31, 2018 and the comparative information.

Accordingly the Financial Statements of the Company with effect from 1st April 2017 have been prepared in accordance with the Indian Accounting Standards (IND AS) notified under the Companies (Accounting Standards) Rules 2015 and Companies (Accounting Standards) Rules 2016, the provisions of Companies Act, 2013, and guidelines issued by the Securities and Exchange Board of India (SEBI). Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use. Financial Statements of the Company are prepared under the historical cost convention on the accrual basis.

The financial statements are presented in Indian Rupees (INR). Amount has been rounded off to nearest Rupee. For the periods upto and including the financial year ended 31st March 2017; the financial Statements were prepared in accordance with the Indian Generally Accepted Accounting Principles (IGAAP) under the historical cost convention on the accrual basis. IGAAP comprises mandatory accounting standards as prescribed by the Companies Act 2013 u/s 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of Companies Act, 2013, and guidelines issued by the Securities and Exchange Board of India (SEBI), Accounting Policies have been consistently applied.

b. Exemptions availed on first time adoption of IND AS 101

IND AS 101 allows first time adopters certain exemptions from the retrospective application of certain requirements under IND AS. The company has accordingly applied the following exemptions:-

(a) Investments in equity shares of unquoted companies:

The Company has elected to adopt the carrying value under previous GAAP as on the date of transition i.e. April 1, 2016 in its financial statements.

(b) Deemed Cost of Property, Plant and Equipment (PPE), Intangible Assets and Investment Property:

There is no change in functional currency of the Company on the date of transition to IND AS, hence Company has elected to continue with the carrying value for all of its property, plant and equipment (PPE), intangible assets and investment property recognized under Indian GAAP as deemed cost at transition date (i.e. 01.04.2016) in the financial statements.

c. USE OF ESTIMATES AND JUDGEMENTS

The preparation of the financial statements is in conformity with IND AS requires management to make estimates, judgments and assumptions. These estimates, judgments and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

made as management becomes aware of changes in circumstances surrounding the estimates. The estimates and underlying assumptions are reviewed on a going concern basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, in the period of the revision and future periods if the revision affects both current and future period.

d. CLASSIFICATION OF EXPENDITURE/INCOME

Except Otherwise Indicated:-

- (i) All expenditure and income are accounted for under the natural heads of account.
- (ii) All expenditure and income are accounted for on accrual basis except when ultimate realisation of income is uncertain.

e. REVENUES

- (i) Revenues from sales of goods are recognized when the significant risk and rewards of the ownership of the goods have been transferred to the buyer, recovery of the consideration is probable, the associated costs and involvement with, the goods and the amount of revenue can be measured reliably. The timing of transfers of risks and rewards normally happen upon shipment.
- (ii) Sales returns / rate differences are adjusted from the sales of the year in which the returns take place / rate differences accepted.
- (iii) Further, revenues are recognized at gross value of consideration received excluding the amount of excise duty, cess ,value added tax and Goods & Service Tax(GST).

f. PROPERTY, PLANT AND EQUIPMENT (PPE)**Recognition and measurement:**

Property, plant and equipment are initially recognized at cost of acquisition or construction after deducting refundable purchase taxes and including the cost directly attributable for bringing the asset to the location and conditions necessary for it to be capable of operating in the manner intended by the management, borrowing cost in accordance with the established accounting policy, cost of restoring and dismantling, if any, initially estimated by the management. After the initial recognition the property, plant and equipment are carried at cost less accumulated depreciation and impairment losses.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss.

The estimated useful lives, residual values and depreciation method are reviewed at each financial year end and the effect of any change is accounted for on prospective basis. Depreciation on plant & equipment's are provided as per below schedule:-

Type of Asset	Period
Factory Building	30 years
Plant & Machinery	15 years
Computer Equipment	3 years
Vehicle	8 years
Furniture & Fixture	10 years

The carrying amount of the all property, Plant and equipment are derecognized on its disposal or when no future economic benefits are expected from its use or disposal and the gain or loss on de-recognition is recognized in the statement of profit & loss.

Advances paid towards the acquisition of property, plant and equipment outstanding at each Balance Sheet date is classified as capital advances and cost of assets not put to use before such date are disclosed under 'capital work-in-progress'.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

The Company has opted for an exemption provided by the Indian Accounting Standard (IND AS)-101. Accordingly the carrying value for all Property, plant and Equipment and Intangibles as recognized in the financial statements, as at the date of transition to IND AS, measured as per previous IGAAP are used as deemed cost as at the date of transition.

g. INVENTORIES

Raw materials, stock-in-trade, work-in-progress, finished goods and packing materials are valued at the lower of weighted average cost and net realizable value. Cost of finished goods and work-in-progress includes cost of materials, direct labour and an appropriate portion of overheads to bring the inventory to the present location and condition. Stores and maintenance spares are valued at average cost.

The net realizable value of work-in-progress is determined with reference to the selling price of related finished goods. Raw materials and other supplies held for use in production of inventories are not written down below cost except in cases where material prices have declined and it is estimated that the cost of the finished products will exceed their net realizable value.

Finished goods expiring within 90 days(near expiry inventory) as at the balance sheet date have been fully provided for.

h. TRADE RECEIVABLES

Trade receivables represents amount billed to customers as credit sales and are net off;

- a. any amount billed but for which revenues are reversed under the different accounting standard and
- b. impairment for trade receivables, which is estimated for amounts not expected to be collected in full.”

i. FINANCIAL INSTRUMENTS**Initial recognition**

Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and financial liabilities are recognized at fair value on initial recognition except for trade receivables/ trade payables which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities that are not at fair value through profit and loss are added or deducted to/from the fair value on initial recognition.

Subsequent measurement

(a) Financial assets are subsequently measured at amortised cost if these are held within a business model whose objective is to hold the assets in order to collect contractual cash flows and the contractual terms of the financial assets give rise on specific dates to cash flows that are solely payments of principal and interest on the principal amount outstanding using the effective interest rate (EIR) method. The EIR amortisation is included in finance income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of Profit and Loss.

(b) Financial assets at fair value through profit or loss The financial assets are measured at fair value through profit or loss unless it is classified at amortised cost.

(c) Financial liabilities

- (i) Financial liabilities are initially recognized at the fair value of the consideration received less directly attributable transaction cost.
- (ii) Subsequent to initial measurement, financial liabilities are measured at amortised cost. The difference in the initial carrying amount of the financial liabilities and their redemption value is recognized in the statement of profit & loss over the contractual term using the effective interest rate method. This category includes the following class of liabilities; trade and other payables, borrowing; and other financial liabilities.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

- (iii) Financial liabilities are further classified as current and non-current depending whether they are payable within 12 months after the balance sheet date or beyond.
- (iv) Financial liabilities are derecognized when the company is discharge from its obligation; they expire, are cancelled or replaced by a new liability with substantial modified terms

De-recognition of financial instruments

A financial asset is de-recognised when:

- The rights to receive cash flows from the asset have expired, or
- the Company has transferred substantially all the risks and rewards of the asset, or the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

A financial liability or a part of financial liability is de-recognised from the Balance Sheet when the obligation specified in the contract is discharged, cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

j. IMPAIRMENT**Financial assets**

The company recognizes loss allowances using the expected credit loss model for the financial assets which are not fair valued through statement of profit and loss. Loss allowance on trade receivables, with no significant financing component is measured at an amount equal to lifetime expected credit loss. For all financial assets expected credit losses are measured at an amount equal to 12-month ECL unless there has been significant increase in credit risk from initial recognition in which case these are measured at lifetime expected credit loss. The amount of expected credit losses or reversal that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized is recognized as an impairment gain or loss in the profit or loss for the period.

Intangible assets, property, plant and equipment

Intangible assets, property plant & equipment are evaluated for recoverability wherever events or changes in circumstances indicate that their carrying amount may not be recoverable.

For impairment testing, assets that do not generate independent cash flows are grouped together into cash generating units (CGUs).

For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value in use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the CGU to which the asset belongs.

If such asset is considered to be impaired, the impairment to be recognized in the statement of profit and loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset. An impairment loss is reversed in the statement of profit & losses if there have been changes in the estimates used to determine the recoverable amount. The carrying amount is increased to its revised recoverable amount, provided that this amount does not exceeds the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss has been recognized for the asset in prior years.

k. EARNING PER SHARE

Basic Earnings Per Share is computed by dividing the net profit attributable to the equity shareholders of the company to the weighted average number of Shares outstanding during the period & Diluted earnings per share is computed by dividing the net profit attributable to the equity shareholders of the company after adjusting the effect of all dilutive potential equity shares that were outstanding during the period, the weighted average number of shares outstanding during the period including the weighted average number of equity shares that could have issued upon conversion of all dilutive potential.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018**I. INCOME TAXES****(i) CURRENT TAX**

Income tax expense comprises current and deferred income tax. Income tax expense is recognized in net profit in the statement of profit and loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in other comprehensive income.

Current tax is expected tax payable on the taxable income for the year, using the tax rate enacted at the reporting date, and any adjustment to the tax payable in respect of the earlier periods. Current tax assets and liabilities are offset where the company has legal enforceable right to offset and intends either to settle on net basis, or to realise the assets and settle the liability simultaneously.

(ii) DEFERRED TAX ASSETS / LIABILITIES

Deferred tax is recognized for all taxable temporary differences and is calculated based on the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

Deferred tax is measured at the tax rates that are expected to be applied when the asset is realised or the liability is settled, based on the laws that have been enacted or substantively enacted at the reporting date.

Deferred tax assets are recognized only to the extent that it is probable that future taxable profits will be available against which the assets can be utilised. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset and when the deferred tax balances relate to taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but the Group intends to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

(iii) CURRENT AND DEFERRED TAX FOR THE YEAR

Current and deferred tax are recognized in the statement of profit & loss, except when they relates to items that are recognized in other comprehensive income or directly in equity, in which case, the current tax and deferred tax is recognized directly in other comprehensive income or equity respectively.

m. EMPLOYEES BENEFITS

The company provides for the various benefits plans to the employees. These are categorized into defined benefits plans and defined contributions plans. Defined benefit plans includes the amount paid by the company towards the liability for Provident fund to the employees provident fund organization and Employee State Insurance fund in respect of ESI and defined benefits plans includes the retirement benefit such as gratuity and company absentees both accumulated and non-accumulated.

(i) In respect of Defined Contribution Plans contribution made to the specified fund based on the services rendered by the employees are charged to Statement of Profit & Loss in the year in which services are rendered by the employee.

(ii) Liability in respect of Defined Long Term benefit plan is determined at the present value of the amounts payable determined using actuarial valuation techniques performed by an independent actuarial at each balance sheet date using the projected unit credit methods. Gains and losses through re-measurements of the net defined benefit liability/assets are recognized in other comprehensive income. Past Service cost is recognized in the statement of profit & loss in the period of plan amendment.

(iii) Liabilities for accumulating paid absences is determined at the present value of the amounts payable determined using the actuarial valuation techniques performed by an independent actuarial at each balance sheet date using the projected unit credit method. Actuarial gain or losses in respect of accumulating paid absences are charged to statement of profit & loss account.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

(iv) Liabilities for short term employee benefits are measured at undiscounted amount of the benefits expected to be paid and charged to Statement of Profit & Loss in the year in which the related service is rendered.

n. PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS

(i) A provision is recognized, if as a result of past event the company has present legal or constructive obligations that is reasonably estimable and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to liability.

(ii) A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Contingent Assets are neither recognized nor disclosed in the financial statements.

These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

o. DEPRECIATION

(i) Normal depreciation on all property, plant & equipment except Land are provided from the date of put to use for commercial production on Straight Line Method at the useful lives prescribed in Schedule-II to The Companies Act, 2013 and after providing for the residual value (maximum to the extent of 5%) of the Fixed Assets as determined by the management.

(ii) Depreciation/Amortization on addition /deletions to Fixed Assets is provided on pro-rata basis from/to the date of addition/deletions.

(iii) Depreciation/Amortization on additions/deletions to the fixed assets due to exchange rate fluctuation is provided on pro-rata basis since inception.

(iv) The estimated useful lives, residual values and depreciation method are reviewed at each financial year end and the effect of any change is accounted for on prospective basis.

p. PURCHASES

(i) Purchases returns / rebates are adjusted from the purchases of the year in which the returns take place / rebates allowed.

(ii) Purchases are accounted for "Net of VAT Credit/GST availed on eligible inputs".

q. CLAIMS BY/AGAINST THE COMPANY

Claims by/ against the Company arising on any account are provided for in the accounts on receipts/acceptances.

r. BORROWING COST

Borrowing cost are interest and other costs (including exchange differences relating to foreign currency borrowings to the extent they are regarded as an adjustment to interest costs) incurred in connection with the borrowing of funds. Borrowing cost directly attributable to the acquisition or construction of qualifying /eligible assets, intended for commercial production are capitalised as part of the cost of such assets. All other borrowing costs are recognized as an expense in the year in which they are incurred.

s. STATEMENT OF CASH FLOWS

Statement of Cash Flows is made using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, financing and investing activities of the Company are segregated.

t. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Company's principal financial liability includes Borrowings, Trade payable and other financial liabilities. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include Trade receivables, Cash and cash equivalents and other financial assets that derive directly from its operations. The Company is exposed to credit risk, liquidity risk and Interest rate risk & market risk. The Company's senior management oversees the management of these risks and the appropriate financial risk governance framework for the Company. The senior management provides assurance that the Company's financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with the Company's policies and risk objectives.

The Board of Directors reviewed policies for managing each of these risks, which are summarized below:

(i) Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss.

The impairment for financial assets are based on assumptions about risk of default and expected loss rates. The Company uses judgment in making these assumptions and selecting the inputs to the impairment calculation, based on the Company's past history, existing market conditions as well as forward looking estimates at the end of each balance sheet date. Financial assets are written off when there is no reasonable expectation of recovery, however, the Company continues to attempt to recover the receivables. Where recoveries are made, these are recognized in the Statement of Profit and Loss.

(ii) Liquidity Risk

Liquidity risk refers to the probability of loss arising from a situation where there will not be enough cash and/or cash equivalents to meet the needs of depositors and borrowers, sale of illiquid assets will yield less than their fair value and illiquid assets will not be sold at the desired time due to lack of buyers. The primary objective of liquidity management is to provide for sufficient cash and cash equivalents at all times and any place in the world to enable us to meet our payment obligations.

(iii) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's borrowings obligations with floating interest rates.

u. Accounting Policies not specifically referred to are in accordance with generally accepted accounting principles.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018
2 Reconciliations

The following reconciliations provide the effect of transition to IND AS from IGAAP in accordance with IND AS 101:-

2.1 Equity as at April 1, 2016 and March 31, 2017

2.2 Total Comprehensive Income for the year ended March 31, 2017

2.1 Reconciliation of equity as previously reported under IGAAP to IND AS

Particulars	Note	(Rs. In lacs)					
		Opening balance Sheet as at April 1, 2016			Opening balance Sheet as at March 31, 2017		
		IGAAP	Effects of transition to IND AS	IND AS	IGAAP	Effects of transition to IND AS	IND AS
ASSETS							
NON CURRENT ASSETS							
PROPERTY, PLANT AND EQUIPMENT		763.51		763.51	705.88		705.88
CAPITAL WORK IN PROGRESS		615.20		615.20	551.01		551.01
FINANCIAL ASSETS							
INVESTMENTS		92.30		92.30	92.30		92.30
OTHER NON CURRENT ASSETS	A	-	0.86	0.86	-	0.61	0.61
CURRENT ASSETS							
INVENTORIES		753.10		753.10	113.26		113.26
FINANCIAL ASSETS							
TRADE RECEIVABLES		427.19		427.19	414.33		414.33
CASH AND CASH EQUIVALENTS		3.12		3.12	5.53		5.53
LOANS	B	202.52	(0.86)	201.66	210.29	(0.61)	209.68
OTHER CURRENT ASSETS		0.40		0.40	0.46		0.46
TOTAL ASSETS		2,857.34	-	2,857.34	2,093.06	-	2,093.06
EQUITY AND LIABILITIES							
EQUITY							
EQUITY SHARE CAPITAL		1,911.14	-	1,911.14	1,911.14	-	1,911.14
OTHER EQUITY		(12.84)		(12.84)	(750.19)		(750.19)
LIABILITIES							
NON CURRENT LIABILITIES							
FINANCIAL LIABILITIES							
BORROWINGS		97.60		97.60	-		-
PROVISIONS		18.41		18.41	12.78		12.78
DEFERRED TAX LIABILITIES		97.99		97.99	92.34		92.34
CURRENT LIABILITIES							
FINANCIAL LIABILITIES							
TRADE PAYABLES		64.42		64.42	36.31		36.31
OTHER FINANCIAL LIABILITIES		289.52		289.52	289.52		289.52
PROVISIONS							
OTHER CURRENT LIABILITIES		391.10		391.10	501.16		501.16
TOTAL EQUITY AND LIABILITIES		2,857.34	2,857.34	2,857.34	2,093.06	2,093.06	2,093.06

Explanations for reconciliation of Balance Sheet as previously reported under IGAAP to Ind AS
NOTE A & B

As per IND AS, staff loan and amount and interest accrued thereon are presented/restated at present value applying effective interest rate method and balance is shown separately under other non-current/current assets as deferred cost.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

2.2 Reconciliation of Total Comprehensive Income

		(Rs. In Lacs)			
Sno.	Particulars	Note	Year ended March 31, 2017		
			IGAAP	Effects of transition to IND AS	IND AS
INCOME					
I	Revenue From Operations		284.32	-	284.32
II	Other Income	A	2.43	0.31	2.74
III	Total Income (I+II)		286.75	0.31	287.06
EXPENSES					
IV	Cost of materials consumed		461.70	-	461.70
	Changes in inventories of finished goods, Stock in Trade & work in progress		362.06	-	362.06
	Employee benefits expense	B	77.75	1.73	79.48
	Finance costs		0.09	-	0.09
	Depreciation and amortization expense		59.03	-	59.03
	Other expenses		69.12	-	69.12
	Total expenses (IV)		1,029.75	1.73	1,031.48
V	Profit/(loss) before exceptional items and tax (III-IV)		(743.00)	(1.42)	(744.42)
VI	Exceptional Items		-	-	-
VII	Profit/(loss) before tax (V-VI)		(743.00)	(1.42)	(744.42)
	Tax expense:				
VIII	(1) Current tax		-	-	-
	(2) Deferred tax		5.65	-	5.65
IX	Profit (Loss) after Tax		(737.35)	(1.42)	(738.77)
X	Other Comprehensive Income				
	Actuarial Gain/(Loss)		-	1.42	-
XI	Total Comprehensive Income for the period		(737.35)	-	(738.77)

Explanation for reconciliation of total Comprehensive Income

- A As per IND AS Interest on Staff Loan to be shown on Present value applying effective interest rate method, accordingly amortized interest has been shown in Other Income
- B As per Ind As 19- Employee Benefits, actuarial gains and losses are recognized in other comprehensive income and not reclassified to profit and loss in a subsequent period. Accordingly , the amount of Rs. 1.42 Lacs has been reclassified from the employee benefits to other comprehensive income having no impact on total comprehensive income.

NOTE NO. 03

PROPERTY PLANT & EQUIPMENT

Description	Gross Block			Depreciation						Net block		
	As at 01.04.2017	Additions	Adjustment	As at 31-03-2018	Up to 31-03-2017	During the year	Dep. In reserves	Adjust- ment	As at 31-3-2018	As at 31-3-2018	As at 31-3-2017	As at 01-04-2016
Land	48,40,000	-	-	48,40,000	-	-			-	48,40,000	48,40,000	48,40,000
Building	5,04,30,770	-	-	5,04,30,770	2,45,88,148	14,31,986			2,60,20,134	2,44,10,636	2,58,42,622	27274608
computer & printer	1,45,007		-	1,45,007	1,35,592	2,166		-	1,37,758	7,249	9,415	24855
Furniture & fixtures	2,47,184	-	-	2,47,184	2,24,899	2,027		-	2,26,926	20,258	22,285	24312
vehicles	57,13,418		-	57,13,418	24,99,245	6,95,902			31,95,147	25,18,271	32,14,173	3910075
plant & machinery	10,02,45,253		-	10,02,45,253	6,35,86,083	37,49,420		-	6,73,35,503	3,29,09,750	3,66,59,170	40277268
				-					-			
Total Tangible Assets	16,16,21,632	-	-	16,16,21,632	9,10,33,967	58,81,501	-	-	9,69,15,468	6,47,06,164	7,05,87,665	7,63,51,118
Advance agt. Godown under pogress	5,19,83,840	-	(30,37,000)	4,89,46,840	-	-			-	4,89,46,840	5,19,83,840	58403000
Capital WIP	31,17,184			31,17,184					-	31,17,184	31,17,184	3117184
Total Capital WIP	5,51,01,024			5,20,64,024						5,20,64,024	5,51,01,024	6,15,20,184
This Year	21,67,22,656	-	(30,37,000)	21,36,85,656	9,10,33,967	58,81,501	-	-	9,69,15,468	11,67,70,188	12,56,88,689	13,78,71,302
Previous Year	22,30,02,174	1,39,642	(64,19,160)	21,67,22,656	8,51,30,872	59,03,095			9,10,33,967	12,56,88,689	13,78,71,302	14,35,73,318

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

Non Current Assets

Notes to Financial Statements	As at 31.03.18(Rs.)	As at 31.03.17(Rs.)	As at 01.04.16(Rs.)
Note No. 4			
Non Current Investments			
Shares of Un-quoted Companies:			
25000 equity shares of A.G.Fats Ltd.	25,00,000	25,00,000	25,00,000
50000 equity shares of Braham Hosiery P Ltd.	5,00,000	5,00,000	5,00,000
85000 equity Shares of R.N.Knitfab (P) Ltd.	8,50,000	8,50,000	8,50,000
538000 equity Shares of India Securities Ltd.	53,80,000	53,80,000	53,80,000
Note No. 5	92,30,000	92,30,000	92,30,000
Other Non Current Assets			
Deferred cost toward staff loan	38,259	61,366	86,123
	38,259	61,366	86,123
Current Assets			
Note No. 6			
INVENTORIES			
(As valued and certified by the Management at lower of cost or net realisable value)			
Raw Materials & Packing Materials	8,55,282	12,40,435	2,89,29,949
Store & Spares	48,73,220	49,62,450	50,50,689
Finished Goods	-	27,89,695	3,92,85,500
Work in Process	16,660	23,33,930	20,44,000
Financial Assets	57,45,162	1,13,26,510	7,53,10,138
Note No. 7			
Trade Receivables			
(Unsecured and considered Good)			
Exceeding Six months	3,51,43,904	3,86,77,249	3,51,34,372
Less than Six months	34,23,860	27,55,525	75,84,475
	3,85,67,764	4,14,32,774	4,27,18,847
Note No. 8			
Cash & Cash Equivalents			
Cash in hand	3,270	8,593	2,80,855
Balance with scheduled Banks			
- in Current Accounts	1,52,241	5,44,028	31,026
	1,55,511	5,52,621	3,11,881
Note No. 9			
Current Loans			
(Unsecured considered good)			
Advances recoverable in cash or in kind or for value to be received	1,44,45,196	1,55,56,499	1,51,09,039
Excise/GST Deposit A/c	60,09,082	47,83,016	43,32,831
Tax Deducted at Source	21,912	1,14,923	2,18,665
Security Deposit	2,98,279	2,98,279	2,98,279
VAT Inputs receivable a/c	2,25,185	2,15,699	2,07,280
	2,09,99,654	2,09,68,416	2,01,66,094

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

Current Assets				(Rs.)
Notes to Financial Statements	As at 31.03.18	As at 31.03.17	As at 01.04.16	
Financial Assets				
Note No. 10				
Other Current Assets				
Service Tax Receivable A/c	-	10,506		10,506
Prepaid Expenses	31,861	35,510		29,538
	31,861	46,016		40,044
Note No. 11				
Equity Share Capital				
A) <u>AUTHORISED</u>				
2,00,00,000 Equity Shares of Rs. 10/- each	20,00,00,000	20,00,00,000		20,00,00,000
(Previous year 2,00,00,000 Equity Share of Rs. 10/- each)	20,00,00,000	20,00,00,000		20,00,00,000
B) <u>ISSUED, SUBSCRIBED AND PAID UP</u>				
1,91,11,400 Equity Shares of Rs. 10/- each	19,11,14,000	19,11,14,000		19,11,14,000
(Previous year 1,91,11,400 Equity Share of Rs. 10/- each)	19,11,14,000	19,11,14,000		19,11,14,000

a) Reconciliation of number of shares and amount outstanding at the commencement and at the end of reporting year

Particulars	As at 31.03.2018		As at 31.03.2017		As at 31.03.2016	
	Number of shares	Amount	Number of shares	Amount	Number of shares	Amount
Balance at the commencement of the year	1,91,11,400	19,11,14,000	1,91,11,400	19,11,14,000	1,50,28,750	15,02,87,500
Add :Equity Shares issued in pursuant to conversion of fully convertible warrants to promoters & non promoters on 15.05.2015.	—	—	—	—	40,82,650	4,08,26,500
Balance at the end of the year	1,91,11,400	19,11,14,000	1,91,11,400	19,11,14,000	1,91,11,400	19,11,14,000

b) Details of shares held by shareholders holding more than 5% of the aggregate shares in the company :-

Sno	Name of Shareholder	As at 31.03.2018		As at 31.03.2017		As at 31.03.2016	
		No. of shares	%	No. of shares	%	No. of shares	%
1.	M/s Omkam Pharmaceuticals Pvt Ltd	49,02,322	25.65%	49,02,322	25.65%	49,02,322	25.65%
2.	M/s Dhuru Builders & Promoters Pvt Ltd	26,05,270	13.63%	26,05,270	13.63%	26,29,000	13.76%
3.	M/s Patliputra International Ltd.	26,29,000	13.76%	26,29,000	13.76%	26,29,000	13.76%
4.	Mr. Peeyush Kumar Aggarwal	19,57,159	10.24%	19,57,159	10.24%	19,57,159	10.24%
5.	Mr. Subramanian P	12,82,992	6.71%	--	--	--	--

c) The Company has one class of equity shares having a par value of Rs. 10/- each. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

Notes to Financial Statements	As at 31.03.18 (Rs.)	As at 31.03.17 (Rs.)	As at 01.04.16 (Rs.)
Note No. 12			
Other Equity			
<u>Profit & Loss Account (As per last Balance Sheet)</u>	(7,50,46,621)	(13,12,443)	1,05,87,980
Add: Net Profit/(Loss) for the current year including Comprehensive Income	(84,94,197)	(7,37,34,178)	(1,19,00,423)
<u>Capital Reserve Account</u>			
Share Forfeiture Account	27,500	27,500	27,500
Total Reserve & Surplus carried forwarded to Balance Sheet	(8,35,13,318)	(7,50,19,121)	(12,84,943)

Borrowings

Notes to Financial Statements	As at 31.03.18 (Rs.)		As at 31.03.17 (Rs.)		As at 01.04.16 (Rs.)	
	Non-Current	Current	Non-Current	Current	Non-Current	Current
Note No. 13						
<u>Non Current Borrowings</u>						
SECURED LOANS						
Term Loan	-	3,74,98,531	-	3,74,98,531	97,60,531	2,77,38,000
Indian Overseas Bank (secured by first charge on Land, Building & Plant & Machinery) Current maturity of Long Term Debts are classified under other current liabilities.						
	-	3,74,98,531	-	3,74,98,531	97,60,531	2,77,38,000

- (a) Term loan consisting three loans, financed by Indian Overseas Bank are secured on first paripassu charge basis (a) by way of hypothecation of movable fixed assets of the company and (b) by mortgage of immovable properties of the Company; situated at 138, Roz KaMeo Industrial Area, Sohna, Gurgaon, Haryana. These loans are also collaterally secured (a) by way of second paripassu charge on stocks & book debts of company and (b) by personal guarantee of one of the director of the company.
- (b) These Term Loans was repayable in consolidated equivalent monthly installment of Rs. 8,17,000/- starting from October, 2012, but due to some financial resistant's, company could not pay few of instalments of Term loans, due to that Term accounts with IOB become NPA. However, company has filed OTS proposal with Indian Overseas Bank and the same is under consideration at the end of Indian Overseas Bank is in the process of filing the OTS proposal with the bank.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

Notes to Financial Statements	As at 31.03.18 (Rs.)	As at 31.03.17 (Rs.)	As at 01.04.16 (Rs.)
Current Borrowings			
SECURED LOANS			
Working Capital Loan	2,89,52,213	2,89,52,213	2,89,52,213
Indian Overseas Bank (Secured by first charge on stocks of Finished Goods, Raw Materials. W.I.P & Sundry Debtors			
	2,89,52,213	2,89,52,213	2,89,52,213

- (c) Working Capital loan availed from Indian Overseas bank are secured on first Parrispassu charges basis by way of hypothecation of stock and book debts (present & future) of the company; and collaterally secured on second paripassu charge (a) by way of hypothecation of fixed assets; (b) by mortgage of immovable properties of the company situated at Roz ka Meo, Sohna, Mewat, Haryana and (c) by personal guarantee of one of the Director of the Company. This account is NPA presently. However, the company is in the process of filing the OTS proposal with the bank.

Notes to Financial Statements	As at 31.03.18 (Rs.)		As at 31.03.17 (Rs.)		As at 01.04.16 (Rs.)	
	Non-Current	Current	Non-Current	Current	Non-Current	Current
Note No. 14						
Non Current Liabilities						
Provisions						
Provision for Employee Benefits						
- Gratuity	11,07,556	1,12,545	9,74,534	1,55,932	13,62,020	-
- Leave Encashment	3,67,344	16,635	3,03,860	67,413	4,79,662	-
	14,74,900	1,29,180	12,78,394	2,23,345	18,41,682	-

Note No. 15

Notes to Financial Statements	As at 31.03.18 (Rs.)	As at 31.03.17 (Rs.)	As at 01.04.16 (Rs.)
DEFERRED TAX LIABILITIES (NET)			
Deferred Tax Liabilities			
Excess of Book WDV of Fixed Assets over Tax WDV of Fixed Assets	77,33,727	96,98,251	98,97,093
Deferred Tax Assets			
Provisions for employee benefits	(4,13,050)	(4,64,037)	(97,438)
Deferred Liabilities (net)	73,20,677	92,34,214	97,99,655

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

Notes to Financial Statements	As at 31.03.18 (Rs.)	As at 31.03.17 (Rs.)	As at 01.04.16 (Rs.)
Note No. 16			
Other Current Liabilities			
Current Maturities of long term debt & Provision	3,76,27,711	3,77,21,876	2,77,38,000
Interest due on borrowings	61,58,578	61,58,578	61,58,578
Salary Payable	4,62,473	3,55,512	4,76,298
Advance received from Customers	53,208	51,81,357	41,99,596
TDS payable	45,316	54,294	25,538
Statutory dues payable	34,428	98,347	54,006
Others payable	4,35,960	5,46,334	4,57,671
	4,48,17,674	5,01,16,298	3,91,09,687

Notes to Financial Statements	As at 31.03.18 (Rs.)	As at 31.03.17 (Rs.)
Note No. 17		
Revenue from operations		
Gross Sales	3,99,81,562	2,40,47,408
Less : Excise Duty	-	13,61,173
Other Operating Revenue		
- Income from Job work	9,56,600	57,46,150
Total Revenue from Operations	4,09,38,162	2,84,32,385

Note No. 18		
Misc. Income		
Export incentive & other misc income	5,51,045	2,43,664
Interest Income Staff loan (Amortisation)	38,259	30,683
	5,89,304	2,74,347

Note No. 19		
Cost of Material Consumed		
Raw,Packing & Store & spares inventory at the beginning of the year	62,02,885	3,39,80,638
Purchases during the year	2,95,65,541	1,82,06,091
Inventory at the end of the year	(57,28,502)	(62,02,885)
Freight & Cartage Inward	1,28,960	1,86,638
T O T A L	3,01,68,884	4,61,70,482

Note No. 20		
Change in Inventories of Finished Goods & WIP		
Change in Work in Progress	23,17,270	(2,89,930)
Charges in Stock of Finished Goods	27,89,695	3,64,95,805
T O T A L	51,06,965	3,62,05,875

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

Notes to Financial Statements	As at 31.03.18 (Rs.)	As at 31.03.17 (Rs.)
Note No. 21		
Employees Benefit		
Salary & Wages	58,64,093	72,65,762
Other allowance & benefits to employees	2,68,683	3,00,830
Employer contribution to PF, ESI & welfare fund	2,46,084	2,24,481
Staff welfare	94,676	1,22,583
Medical expenses	2,394	3,708
Interest Exp Staff loan (Amortisation)	38,259	30,683
	65,14,189	79,48,047
Note No. 22		
FINANCE CHARGES		
Others	16,689	8,794
	16,689	8,794
Note No. 23		
Other Expenses		
Advertisement	63,892	72,787
AGM exps.	735	880
Audit fee	85,000	97,750
Bank Charges	6,124	4,135
Books, Newspapers & Periodicals	11,205	1,518
Business Promotion Expenses	58,183	15,885
Conveyance expenses	1,07,246	1,67,159
Diwali Expenses	27,789	1,78,648
Factory & General Insurance	1,28,021	1,37,480
General repair & maintenance	46,713	45,091
Legal & Professional expenses	1,58,965	1,27,700
Miscellaneous expenses	1,72,248	68,802
Packing & Forwarding Expenses	1,76,755	2,22,065
Postage & telegram	6,203	11,298
Power & Fuel	11,78,164	20,69,151
Printing & Stationery	50,655	48,996
Rates & Taxes & other fee's	4,35,854	3,56,608
Rent	7,77,640	18,66,336
Repair & maintenance to building	30,101	1,62,364
Repair & maintenance to Plant & Machineries	98,940	3,81,525
Security Service	6,03,091	6,15,202
Telephone expenses	85,003	1,08,894
Testing Charges	24,551	30,853
Travelling expenses	2,960	26,299
Vehicle expenses	21,000	45,000
Water & Electricity	50,980	49,727
	44,08,018	69,12,153

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018**NOTE NO. 24****CONTINGENT LIABILITIES (to the extent not provided for)**

(Rs. In lacs)

Particulars	As at 31.03.2018	As at 31.03.2017
Bank Interest on Cash Credit & Term Loan (not acknowledge as debts) due to NPA of account.	398.16	259.73
Demand raised by Hardik Distributors, Bhopal. Litigation is pending with High Court, MP	4.20	4.20

NOTE NO. 25 Segment Disclosure**(a) Business Segment:**

The Company is engaged primarily in pharmaceuticals business and there are no separate reportable segments as per IND AS-108.

(b) Geographical Segment:

(Rs. in lacs)

Particulars	As at 31 st March, 2018	As at 31 st March, 2017
Sales revenue(net)		
-In India	399.82	226.86
-Outside India	--	--
	399.82	226.86

NOTE NO. 26**Employee Benefits**

Brief description of the Plans: The Company has various schemes for long term benefits such as Provident Fund, Gratuity, and Leave Encashment. The Company's defined contribution plans are Provident Funds, Employee's State Insurance Fund & Employee's Pension Scheme (under the provision of Provident Funds & Miscellaneous Provisions Act, 1952). The Company has no further obligation beyond making the contributions. The Company's defined benefit plans include Gratuity & Leave Encashment Plan. In accordance with the applicable Indian Laws, the company provides for gratuity for all employees. The Gratuity Plan provides a lump sum payment to vested employees, at retirement or termination of employment, an amount based on respective employee's last drawn salary & for the years of employment with the Company. During the year company has computed his liability through Actuarial Valuar M/s Charan Gupta Consultants Pvt Ltd. The present value of obligation for Gratuity & other Post Employment benefit (i.e. Leave encashment) are determined based on actuarial valuation using the Projected Unit Credit Method. The additional disclosure in terms of Indian Accounting Standards-19 "Employees Benefits" is as under:.

Reconciliation of Opening & Closing balance of Obligation

(Rs. In lacs)

Particulars	Gratuity A/c	Leave Encashment A/c
Obligation at the beginning of the year	11.30	3.71
Current Service Cost	0.83	0.32
Interest Cost	1.21	0.27
Actuarial (gain)/loss	(1.14)	(0.46)
Less: Benefits paid	--	--
Obligation at the end of the year	12.20	3.84

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

Gratuity & other Post Employment benefit cost for the period

Particulars	Gratuity A/c	Leave Encashment A/c
Current Service Cost	0.83	0.32
Interest Cost	1.21	0.27
Net Actuarial (gain)/loss recognized in the period	(1.14)	(0.46)
Expenses recognized in the statement of profit & losses	0.90	0.13

27. During the year, banker of the company i.e. Indian Overseas Bank has taken over the possession of immovable property of the director/guarantor of the company to recover its outstanding's from the company due to NPA of our accounts . However, Company has filed OTS proposal to IOB for settling their dues & the same is under consideration at the end of the bank.

28. Necessary disclosures under Micro, Small and Medium Enterprises Development Act 2006, could not be considered for previous years as the relevant information to identify the suppliers who were covered under the said Act were not received from such parties during the previous years.

29. **Statement of Management**

(A) The current assets, loans and advances are good and recoverable and are approximately of the values, if realized in the ordinary courses of business unless and to the extent stated otherwise in the Accounts. Provision for all known liabilities is adequate and not in excess of amount reasonably necessary. However, Company has started its efforts to realize the advances (given to the parties) which are more than one year old.

(B) Balance Sheet and Statement of Profit and Loss read together with Notes to the accounts thereon, are drawn up so as to disclose the information required under the Companies Act, 2013 as well as give a true and fair view of the statement of affairs of the Company as at the end of the year and results of the Company for the year under review.

30. **Payment to Auditors' (Amount in Rs.)**

Particulars	As on 31 st March, 2018	As on 31 st March, 2017
Audit Fee	60,000	60,000
Taxation matters	25,000	25,000
Total (exclusive of Service tax)	85,000	85,000

31. **INVESTMENTS**

Company has sent various notices to the Companies in which the company has made an investment, as neither they are sending duplicate shares certificates nor replying to the letters of the company. The company has misplaced/lost the share certificates of the investments made by it during the shifting of records. As such these shares certificates are not physically held by the company as on 31st March, 2018. Accordingly, company has not calculated the fair value of the investments.

32. Additional information, to the extent applicable, required under paragraphs 5 (viii) (c) of general instructions for preparation of the Statement of profit & Loss as per schedule III to the Companies Act, 2013

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

(A) Composition of Raw Material Consumption:

(Rs. In Lacs)

Raw Material Consumption	2017-2018		2016-2017	
	Value	Percentage	Value	Percentage
Imported	Nil	Nil	Nil	Nil
Indigenous	198.71	100	459.84	100

(B) Value of Imports on CIF basis:-

Particulars	2017-2018	2016-2017
Raw Material	NIL	NIL

(C) Earning in Foreign Currency:

Particulars	2017-2018	2016-2017
F.O.B Value of Exports	NIL	NIL

(D) Expenditure in Foreign Currency (on payment basis):

Particulars	2017-2018	2016-2017
Expenditure in Foreign Currency	NIL	NIL

33. "Related party disclosures as required under Indian Accounting Standard (IAS)-24 & Section 2(76) of the Companies Act,2013

(a). Related parties and nature of related party relationships where control exists

Sno.	Name of the party	Nature of Relationship
1.	Key Managerial Personnel Mr. Peeyush Kumar Aggarwal	Director
2.	Enterprises controlled by Promoter Director	M/S Omkam Global Capital Pvt Ltd

Transactions during the year with related parties

Particulars	Key Managerial Person	Enterprises over which as mentioned above able to excise significant influence
Salary Paid to Manoj Bhatia, CFO	Rs. 4,62,000/-	—
Salary Paid to Pooja Chuni, CS	Rs. 2,60,000/-	
Amount received from M/s Omkam Global Capital Pvt Ltd		30,37,000/-
Amount adjusted/Repaid to M/s Omkam Global Capital Pvt Ltd		30,37,000/-

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2018

34. "Earning per share" computed accordance with Accounting Standard (AS) – 20

(Rs. in lacs)

Particulars	As at 31.03.2018	As at 31.03.2017
Loss after tax	(86.55)	(738.76)
Weighted average number of equity shares outstanding during the year	1,91,11,400	1,91,11,400
Face Value per share (InRs.)	10/-	10/-
Earnings per share(EPS)		
- Basic (In Rs.)	(0.45)	(3.86)
- Diluted (InRs.)	(0.45)	(3.86)

35. The Board of Directors of the Company has not recommended any dividend for the financial year ended 31.03.2018.
36. The balances of loans & advances, sundry debtors and sundry creditors are subject to the confirmation and consequential reconciliation/adjustments arising there from, if any. The management, however, does not accept any material variation.
37. Previous year figures have been regrouped, rearranged wherever necessary to correspond with the current year's classification/disclosure.

For RMA & Associates LLP

For and on behalf of the Board of Directors of Advik Laboratories Ltd.

Chartered Accountants

Firm Regn. No. : 000978N/N500062

Sd/-
(Amit Jain)
Partner
Membership No. 503109

Sd/-
(Peeyush Kumar Aggarwal)
Chairman
DIN:00090423

Sd/-
(Sachin Garg)
Managing Director
DIN:03320351

Sd/-
(Manoj Bhatia)
CFO

Sd/-
(Pooja Chuni)
Company Secretary

Place: New Delhi

Date: 30th May, 2018

ADVIK LABORATORIES LIMITED

CIN: L74899HR1994PLC038300

Regd. Office: 138, Roz- Ka - Meo, Industrial Area Sohna, Distt. Mewat-122103 (Haryana)

Phone: 0124-2362471, Email : mail@advikindia.com, Website : www.advikindia.com

E-COMMUNICATION REGISTRATION FORM AND BANK ACCOUNT DETAILS

Dear Shareholders,

You are aware that majority of the provisions of Companies Act, 2013 have been made effective from 1st April, 2014. Pursuant to Section 101 and Section 136 of the Companies Act, 2013 read with relevant Rules issued there under, Companies can serve Annual Reports, Notices and other communications through electronic mode to those shareholders who have registered their email address either with the Company/RTA or with the Depository. It is a welcome move that would benefit the society at large, as this will reduce paper consumption to a great extent and allow shareholders to contribute towards a greener environment. This provides a golden opportunity to every shareholder of Advik Laboratories Limited to contribute to the cause of 'Green Initiative' by giving their consent to receive various communications from the Company through electronic mode.

We therefore invite all our shareholders to contribute to the cause by filling up the form given below to receive communication from the Company in electronic mode. You can also download the appended registration form from the website of the Company www.advikindia.com

[Please note that as a Member of the Company, you will be entitled to receive all such communication in physical form, upon request.]

To support this green initiative in full measure, members who have not registered their E-mail address, PAN Number and Bank Account details so far, are requested to register their E-mail address and PAN Number and Bank account details along with self attested copy of their PAN Card and original cancelled cheque/bank passbook/statement with the company/ RTA.

Best Regards,

Sd/-

Pooja Chuni

Company Secretary

E-COMMUNICATION REGISTRATION FORM AND BANK ACCOUNT DETAILS

Folio No. /DP ID & Client ID:.....

Name of the 1st Registered Holder:.....

Name of the Joint Holder[s]: (1).....(2).....

Registered Address:.....

E-mail ID (to be registered):..... Mob./Tel. No.:.....

PAN:

I/We shareholder(s) of Advik Laboratories Limited hereby agree to receive communications from the Company in electronic mode. Please register my above E-mail ID in your records for sending communications in electronic form.

Date: Signature:

Note: Shareholder(s) are requested to keep the Company informed as and when there is any change in the e-mail address.

Unit: ADVIK LABORATORIES LIMITED

Dear Sir,

I/we hereby request you to update my/our below mentioned details in your records with respect to the shareholding in **ADVIK LABORATORIES LIMITED**

Name of Shareholder(s)			
Folio No.(s)			
PAN	First Holder	Second Holder	Third Holder
Bank Name & Branch Address			
Bank A/c. No.			
IFSC Code			
Email ID			
DP ID/Client ID			

I/we hereby declare that the particulars given hereinabove are correct and complete.

First Holder

Second Holder

Third Holder

Signature of Shareholder(s) - _____

Encl.: 1. Self- attested copy of PAN card of all the Shareholders in case of joint holding.

2. Original cancelled cheque/Bank Passbook/Statement attested by the Bank.

ADVIK LABORATORIES LIMITED

CIN: L74899HR1994PLC038300

Regd. Office: 138, Roz- Ka - Meo, Industrial Area Sohna, Distt. Mewat-122103 (Haryana)

Phone: 0124-2362471, Email : mail@advikindia.com, Website : www.advikindia.com

ATTENDANCE SLIP

(To be handed over at the entrance of the meeting venue)

Name of the Member(s) / Proxy*: (*Strike off whichever is not applicable)

Registered address:.....

E-mail Id: Folio No. /DP ID & Client ID:.....

I/We, being the member (s) of shares of the above named company, hereby record my/our presence at the 24th Annual General Meeting of the Company, to be held on Friday, the 28th day of September, 2018 at 10:00 a.m. at 138, Roz- Ka - Meo, Industrial Area Sohna, Distt. Mewat-122103 (Haryana) and at any adjournment thereof.

Signature of the Member/Proxy*:

(*strike out whichever is not applicable)

NOTES:

- Members/Proxies are requested to bring the duly signed attendance slip to the meeting and hand it over at the entrance.
- Corporate members intending to send their authorized representatives to attend the meeting are requested to send, to the Company, a certified copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the meeting.

ADVIK LABORATORIES LIMITED

CIN: L74899HR1994PLC038300

Regd. Office: 138, Roz- Ka - Meo, Industrial Area Sohna, Distt. Mewat-122103 (Haryana)

Phone: 0124-2362471, Email : mail@advikindia.com, Website : www.advikindia.com

Form No. MGT 11

PROXY FORM

[Pursuant to Section 105 (6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the Member (s):

Registered address:

E-mail Id: Folio No. /DP ID & Client ID:

I/We, being the member (s) of shares of the above named company, hereby appoint

1) Name: E-mail Id:

Address:

..... Signature: or failing him/her

2) Name: E-mail Id:

Address:

..... Signature: or failing him/her

as my/our Proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 24th Annual General Meeting of the Company, to be held on Friday, the 28th day of September, 2018 at 10:00 a.m. at 138, Roz- Ka - Meo, Industrial Area Sohna, Distt. Mewat-122103 (Haryana) and at any adjournment thereof in respect of such resolutions as are indicated overleaf:

Res. No.	Description	For	Against
1.	Adoption of Financial Statements, Board and Auditors' Report for the Financial Year 2017-18.		
2.	Re-appointment of Mr. Sachin Garg, Managing Director of the Company as a Director liable to retire by Rotation.		
3.	Reappointment of M/s RMA & Associates, LLP (Firm Regn no. 000978N/N500062) Chartered Accountants, as the Statutory Auditors of the Company		
4.	Approval of Related Parties U/s 188 of Companies Act, 2013		

Affix Revenue Stamp

Signed this day of 2018. Signature of Shareholder:.....

NOTES:

- Please put a 'X' in the appropriate column against the respective resolutions. If you leave the 'For' or 'Against' column blank against any or all the resolutions, your Proxy will be entitled to vote in the manner as he/she thinks appropriate.
- Pursuant to the provisions of Section 105 of the Companies Act, 2013, a person can act as a proxy on behalf of not more than fifty (50) members and holding in the aggregate not more than ten percent (10%) of the total Share Capital of the Company carrying voting rights. A member holding more than ten percent (10%) of the total Share Capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as proxy for any other member.
- This form of Proxy in order to be effective should be duly completed, stamped, signed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting.

If undelivered, please return to :-

Advik Laboratories Limited
703, Aruanchal Building, 19
Barakhamba Road, Connaught Place
New Delhi – 110 001
Tel nos. : 011-42424884, 011-43571043-45,
Fax : 011-43571047
Email : mail@advikindia.com